2013 ACCF/AHA Guideline for the Management of Heart Failure

Journal of the American College of Cardiology - Tập 62 Số 16 - Trang e147-e239 - 2013
Clyde W. Yancy1, Mariell Jessup2, Biykem Bozkurt2, Javed Butler2, Donald E. Casey3, Mark H. Drazner2, Gregg C. Fonarow2, Stephen A. Geraci4, Tamara B. Horwich2, James L. Januzzi2, Maryl R. Johnson5, Edward K. Kasper2, Wayne C. Levy2, Frederick A. Masoudi6, Patrick E. McBride7, John J.V. McMurray2, Judith E. Mitchell2, Pamela N. Peterson2, Bárbara Riegel2, Flora Sam2, Lynne Warner Stevenson2, W.H. Wilson Tang2, Emily J. Tsai2, Bruce L. Wilkoff8
1ACCF/AHA Task Force on Practice Guidelines Liaison
2ACCF/AHA Representative
3American College of Physicians
4American College of Chest Physicians representative.
5International Society for Heart and Lung Transplantation Representative
6ACCF/AHA Task Force on Performance Measures Liaison
7American Acad. of Family Physicians
8Heart Rhythm Society

Tóm tắt

Từ khóa


Tài liệu tham khảo

2011

2011

Tracy, 2013, J Am Coll Cardiol, 61, e6, 10.1016/j.jacc.2012.11.007

Warnes, 2008, J Am Coll Cardiol, 52, e143, 10.1016/j.jacc.2008.10.001

Fuster, 2011, J Am Coll Cardiol, 57, e101, 10.1016/j.jacc.2010.09.013

Wann, 2011, 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 57, 223, 10.1016/j.jacc.2010.10.001

Wann, 2011, 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, J Am Coll Cardiol, 57, 1330, 10.1016/j.jacc.2011.01.010

Greenland, 2010, 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 56, e50, 10.1016/j.jacc.2010.09.001

Hillis, 2011, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 58, e123, 10.1016/j.jacc.2011.08.009

Gersh, 2011, J Am Coll Cardiol, 58, e212, 10.1016/j.jacc.2011.06.011

Levine, 2011, 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions, J Am Coll Cardiol, 58, e44, 10.1016/j.jacc.2011.08.007

Smith, 2011, AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation, J Am Coll Cardiol, 58, 2432, 10.1016/j.jacc.2011.10.824

Fihn, 2012, J Am Coll Cardiol, 60, e44, 10.1016/j.jacc.2012.07.013

O’Gara, 2013, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 61, 485, 10.1016/j.jacc.2012.11.018

Anderson, 2013, J Am Coll Cardiol, 61, e179, 10.1016/j.jacc.2013.01.014

Bonow, 2008, J Am Coll Cardiol, 52, e1, 10.1016/j.jacc.2008.05.007

Lindenfeld, 2010, HFSA 2010 comprehensive heart failure practice guideline, J Card Fail, 16, e1, 10.1016/j.cardfail.2010.04.004

McMurray, 2012, ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Eur Heart J, 33, 1787, 10.1093/eurheartj/ehs104

National Collaborating Centre for Acute and Chronic Conditions. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (NICE clinical guideline 108). Available at: http://www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf. Accessed March 11, 2013.

Guyatt, 2012, Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 141, 7S, 10.1378/chest.1412S3

Costanzo, 2010, The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients, J Heart Lung Transplant, 29, 914, 10.1016/j.healun.2010.05.034

Maron, 2006, Circulation, 113, 1807, 10.1161/CIRCULATIONAHA.106.174287

Ashley, 2012, Genetics and cardiovascular disease: a policy statement from the American Heart Association, Circulation, 126, 142, 10.1161/CIR.0b013e31825b07f8

Patel, 2013, 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, J Am Coll Cardiol, 61, 2207, 10.1016/j.jacc.2013.02.005

Patel, 2012, J Am Coll Cardiol, 59, 857, 10.1016/j.jacc.2011.12.001

Chobanian, 2003, Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2

2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143

Balady, 2011, Referral, enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond: a presidential advisory from the American Heart Association, Circulation, 124, 2951, 10.1161/CIR.0b013e31823b21e2

Allen, 2012, Decision making in advanced heart failure: a scientific statement from the American Heart Association, Circulation, 125, 1928, 10.1161/CIR.0b013e31824f2173

Peura, 2012, Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association, Circulation, 126, 2648, 10.1161/CIR.0b013e3182769a54

Metra, 2007, Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 9, 684, 10.1016/j.ejheart.2007.04.003

Furie, 2012, Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, 43, 3442, 10.1161/STR.0b013e318266722a

Thygesen, 2012, Third universal definition of myocardial infarction, J Am Coll Cardiol, 60, 1581, 10.1016/j.jacc.2012.08.001

Fonarow, 2007, Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry, J Am Coll Cardiol, 50, 768, 10.1016/j.jacc.2007.04.064

Cleland, 2005, Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction, Heart, 91, ii7

Kannel, 2000, Incidence and epidemiology of heart failure, Heart Fail Rev, 5, 167, 10.1023/A:1009884820941

Hunt, 2009, 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 53, e1, 10.1016/j.jacc.2008.11.013

Kane, 2011, Progression of left ventricular diastolic dysfunction and risk of heart failure, JAMA, 306, 856, 10.1001/jama.2011.1201

Owan, 2006, Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 251, 10.1056/NEJMoa052256

Vasan, 2000, Defining diastolic heart failure: a call for standardized diagnostic criteria, Circulation, 101, 2118, 10.1161/01.CIR.101.17.2118

Steinberg, 2012, Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes, Circulation, 126, 65, 10.1161/CIRCULATIONAHA.111.080770

Lee, 2009, Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute, Circulation, 119, 3070, 10.1161/CIRCULATIONAHA.108.815944

Bhuiyan, 2011, Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma, Curr Cardiovasc Risk Rep, 5, 440, 10.1007/s12170-011-0184-2

Punnoose, 2011, Heart failure with recovered ejection fraction: a distinct clinical entity, J Card Fail, 17, 527, 10.1016/j.cardfail.2011.03.005

1994

Ammar, 2007, Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community, Circulation, 115, 1563, 10.1161/CIRCULATIONAHA.106.666818

Goldman, 1981, Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale, Circulation, 64, 1227, 10.1161/01.CIR.64.6.1227

Madsen, 1994, Chronic congestive heart failure: description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms, Eur Heart J, 15, 303, 10.1093/oxfordjournals.eurheartj.a060495

Djousse, 2009, Relation between modifiable lifestyle factors and lifetime risk of heart failure, JAMA, 302, 394, 10.1001/jama.2009.1062

Go, 2013, Heart disease and stroke statistics–2013 update: a report from the American Heart Association, Circulation, 127, e6

Curtis, 2008, Incidence and prevalence of heart failure in elderly persons, 1994–2003, Arch Intern Med, 168, 418, 10.1001/archinternmed.2007.80

Roger, 2004, Trends in heart failure incidence and survival in a community-based population, JAMA, 292, 344, 10.1001/jama.292.3.344

Owan, 2005, Epidemiology of diastolic heart failure, Prog Cardiovasc Dis, 47, 320, 10.1016/j.pcad.2005.02.010

2011

Bahrami, 2008, Differences in the incidence of congestive heart failure by ethnicity: the Multi-Ethnic Study of Atherosclerosis, Arch Intern Med, 168, 2138, 10.1001/archinte.168.19.2138

Lloyd-Jones, 2002, Lifetime risk for developing congestive heart failure: the Framingham Heart Study, Circulation, 106, 3068, 10.1161/01.CIR.0000039105.49749.6F

Loehr, 2008, Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study), Am J Cardiol, 101, 1016, 10.1016/j.amjcard.2007.11.061

Levy, 2002, Long-term trends in the incidence of and survival with heart failure, N Engl J Med, 347, 1397, 10.1056/NEJMoa020265

Bueno, 2010, Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993–2006, JAMA, 303, 2141, 10.1001/jama.2010.748

Krumholz, 2009, Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission, Circ Cardiovasc Qual Outcomes, 2, 407, 10.1161/CIRCOUTCOMES.109.883256

McDonagh, 1997, Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population, Lancet, 350, 829, 10.1016/S0140-6736(97)03033-X

Mosterd, 1999, Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study, Eur Heart J, 20, 447, 10.1053/euhj.1998.1239

Redfield, 2003, Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic, JAMA, 289, 194, 10.1001/jama.289.2.194

Jong, 2003, Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study, Lancet, 361, 1843, 10.1016/S0140-6736(03)13501-5

Heo, 2008, Predictors and effect of physical symptom status on health-related quality of life in patients with heart failure, Am J Crit Care, 17, 124, 10.4037/ajcc2008.17.2.124

Lesman-Leegte, 2009, Quality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age- and gender-matched community controls, J Card Fail, 15, 17, 10.1016/j.cardfail.2008.09.006

Moser, 2009, Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure, J Card Fail, 15, 763, 10.1016/j.cardfail.2009.05.003

Rodriguez-Artalejo, 2005, Health-related quality of life as a predictor of hospital readmission and death among patients with heart failure, Arch Intern Med, 165, 1274, 10.1001/archinte.165.11.1274

Heo, 2007, Gender differences in the effects of physical and emotional symptoms on health-related quality of life in patients with heart failure, Eur J Cardiovasc Nurs, 6, 146, 10.1016/j.ejcnurse.2006.06.008

Riegel, 2008, Ethnic differences in quality of life in persons with heart failure, J Card Fail, 14, 41, 10.1016/j.cardfail.2007.09.008

Bosworth, 2004, Congestive heart failure patients’ perceptions of quality of life: the integration of physical and psychosocial factors, Aging Ment Health, 8, 83, 10.1080/13607860310001613374

Carmona-Bernal, 2008, Quality of life in patients with congestive heart failure and central sleep apnea, Sleep Med, 9, 646, 10.1016/j.sleep.2007.11.008

Lewis, 2007, Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM, Eur J Heart Fail, 9, 83, 10.1016/j.ejheart.2006.10.012

Masoudi, 2004, Age, functional capacity, and health-related quality of life in patients with heart failure, J Card Fail, 10, 368, 10.1016/j.cardfail.2004.01.009

Pressler, 2010, Cognitive deficits and health-related quality of life in chronic heart failure, J Cardiovasc Nurs, 25, 189, 10.1097/JCN.0b013e3181ca36fe

Majani, 2005, Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial, J Card Fail, 11, 253, 10.1016/j.cardfail.2004.11.004

Cleland, 2005, The effect of cardiac resynchronization on morbidity and mortality in heart failure, N Engl J Med, 352, 1539, 10.1056/NEJMoa050496

Harrison, 2002, Quality of life of individuals with heart failure: a randomized trial of the effectiveness of two models of hospital-to-home transition, Med Care, 40, 271, 10.1097/00005650-200204000-00003

Inglis, 2010, Structured telephone support or telemonitoring programmes for patients with chronic heart failure, Cochrane Database Syst Rev, CD007228

Johansson, 2006, Factors and interventions influencing health-related quality of life in patients with heart failure: a review of the literature, Eur J Cardiovasc Nurs, 5, 5, 10.1016/j.ejcnurse.2005.04.011

McAlister, 2004, Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials, J Am Coll Cardiol, 44, 810

Ditewig, 2010, Effectiveness of self-management interventions on mortality, hospital readmissions, chronic heart failure hospitalization rate and quality of life in patients with chronic heart failure: a systematic review, Patient Educ Couns, 78, 297, 10.1016/j.pec.2010.01.016

Jovicic, 2006, Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials, BMC Cardiovasc Disord, 6, 43, 10.1186/1471-2261-6-43

Chien, 2008, Home-based exercise increases exercise capacity but not quality of life in people with chronic heart failure: a systematic review, Aust J Physiother, 54, 87, 10.1016/S0004-9514(08)70041-2

Karapolat, 2009, Comparison of hospital-based versus home-based exercise training in patients with heart failure: effects on functional capacity, quality of life, psychological symptoms, and hemodynamic parameters, Clin Res Cardiol, 98, 635, 10.1007/s00392-009-0049-6

Heidenreich, 2011, Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association, Circulation, 123, 933, 10.1161/CIR.0b013e31820a55f5

Titler, 2008, Cost of hospital care for older adults with heart failure: medical, pharmaceutical, and nursing costs, Health Serv Res, 43, 635, 10.1111/j.1475-6773.2007.00789.x

Wang, 2010, Costs of heart failure-related hospitalizations in patients aged 18 to 64 years, Am J Manag Care, 16, 769

2012, Standards of medical care in diabetes–2012, Diabetes Care, 35, S11

Levy, 1996, The progression from hypertension to congestive heart failure, JAMA, 275, 1557, 10.1001/jama.1996.03530440037034

Wilhelmsen, 2001, Heart failure in the general population of men: morbidity, risk factors and prognosis, J Intern Med, 249, 253, 10.1046/j.1365-2796.2001.00801.x

1970, Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg, JAMA, 213, 1143, 10.1001/jama.1970.03170330025003

Kostis, 1997, Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group, JAMA, 278, 212, 10.1001/jama.1997.03550030052033

Izzo, 2004, Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure, Med Clin North Am, 88, 1257, 10.1016/j.mcna.2004.06.002

Baker, 2002, Prevention of heart failure, J Card Fail, 8, 333, 10.1054/jcaf.2002.0805333

Vasan, 2002, Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study, JAMA, 287, 1003, 10.1001/jama.287.8.1003

Taegtmeyer, 2002, Adaptation and maladaptation of the heart in diabetes: part I: general concepts, Circulation, 105, 1727, 10.1161/01.CIR.0000012466.50373.E8

Kenchaiah, 2002, Obesity and the risk of heart failure, N Engl J Med, 347, 305, 10.1056/NEJMoa020245

He, 2001, Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study, Arch Intern Med, 161, 996, 10.1001/archinte.161.7.996

Krumholz, 2000, Predictors of readmission among elderly survivors of admission with heart failure, Am Heart J, 139, 72, 10.1016/S0002-8703(00)90311-9

Shindler, 1996, Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry, Am J Cardiol, 77, 1017, 10.1016/S0002-9149(97)89163-1

Kereiakes, 2003, Metabolic syndrome epidemic, Circulation, 108, 1552, 10.1161/01.CIR.0000093203.00632.2B

Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, J Am Coll Cardiol, 44, 720, 10.1016/j.jacc.2004.07.001

Richardson, 1996, Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies, Circulation, 93, 841, 10.1161/01.CIR.93.5.841

Manolio, 1992, Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop), Am J Cardiol, 69, 1458, 10.1016/0002-9149(92)90901-A

Adams, 2005, Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE), Am Heart J, 149, 209, 10.1016/j.ahj.2004.08.005

Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713

Ghali, 2002, Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF), Circulation, 105, 1585, 10.1161/01.CIR.0000012546.20194.33

Dries, 1999, Racial differences in the outcome of left ventricular dysfunction, N Engl J Med, 340, 609, 10.1056/NEJM199902253400804

Nieminen, 2008, Gender related differences in patients presenting with acute heart failure: results from EuroHeart Failure Survey II, Eur J Heart Fail, 10, 140, 10.1016/j.ejheart.2007.12.012

Dec, 1994, Idiopathic dilated cardiomyopathy, N Engl J Med, 331, 1564, 10.1056/NEJM199412083312307

McNamara, 2011, Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study, J Am Coll Cardiol, 58, 1112, 10.1016/j.jacc.2011.05.033

Ehlert, 2001, Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmias: differences in presentation and outcome in the AVID registry, Am Heart J, 142, 816, 10.1067/mhj.2001.119137

Abraham, 2004, Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure, Circulation, 110, 2864, 10.1161/01.CIR.0000146336.92331.D1

Bristow, 2004, Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure, N Engl J Med, 350, 2140, 10.1056/NEJMoa032423

1999, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9

Hershberger, 2011, Update 2011: clinical and genetic issues in familial dilated cardiomyopathy, J Am Coll Cardiol, 57, 1641, 10.1016/j.jacc.2011.01.015

Petretta, 2011, Review and metaanalysis of the frequency of familial dilated cardiomyopathy, Am J Cardiol, 108, 1171, 10.1016/j.amjcard.2011.06.022

Judge, 2010, Use of genetics in the clinical evaluation and management of heart failure, Curr Treat Options Cardiovasc Med, 12, 566, 10.1007/s11936-010-0092-7

Hershberger, 2009, Genetic evaluation of cardiomyopathy: a Heart Failure Society of America practice guideline, J Card Fail, 15, 83, 10.1016/j.cardfail.2009.01.006

Charron, 2010, Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 31, 2715, 10.1093/eurheartj/ehq271

Ackerman, 2011, HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA), Europace, 13, 1077, 10.1093/europace/eur245

Alpert, 2001, Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome, Am J Med Sci, 321, 225, 10.1097/00000441-200104000-00003

Marfella, 2009, Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome, J Lipid Res, 50, 2314, 10.1194/jlr.P900032-JLR200

Schulze, 2009, Myocardial lipid accumulation and lipotoxicity in heart failure, J Lipid Res, 50, 2137, 10.1194/jlr.R001115

Aguilar, 2009, Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes, J Am Coll Cardiol, 54, 422, 10.1016/j.jacc.2009.04.049

Eurich, 2007, Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review, BMJ, 335, 497, 10.1136/bmj.39314.620174.80

Aguilar, 2007, The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure, J Am Coll Cardiol, 50, 32, 10.1016/j.jacc.2007.01.096

Masoudi, 2005, Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study, Circulation, 111, 583, 10.1161/01.CIR.0000154542.13412.B1

Misbin, 1998, Lactic acidosis in patients with diabetes treated with metformin, N Engl J Med, 338, 265, 10.1056/NEJM199801223380415

Nesto, 2003, Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association, Circulation, 108, 2941, 10.1161/01.CIR.0000103683.99399.7E

Klein, 2001, Thyroid hormone and the cardiovascular system, N Engl J Med, 344, 501, 10.1056/NEJM200102153440707

Lee, 1990, Depressed left ventricular systolic ejection force in hypothyroidism, Am J Cardiol, 65, 526, 10.1016/0002-9149(90)90826-M

Colao, 2001, Growth hormone and the heart, Clin Endocrinol (Oxf), 54, 137, 10.1046/j.1365-2265.2001.01218.x

Piano, 2002, Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology, Chest, 121, 1638, 10.1378/chest.121.5.1638

Cerqueira, 1991, Rarity of preclinical alcoholic cardiomyopathy in chronic alcoholics less than 40 years of age, Am J Cardiol, 67, 183, 10.1016/0002-9149(91)90442-N

Faris, 2003, Influence of gender and reported alcohol intake on mortality in nonischemic dilated cardiomyopathy, Heart Dis, 5, 89, 10.1097/01.HDX.0000061702.79961.47

Abramson, 2001, Moderate alcohol consumption and risk of heart failure among older persons, JAMA, 285, 1971, 10.1001/jama.285.15.1971

Walsh, 2002, Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study, Ann Intern Med, 136, 181, 10.7326/0003-4819-136-3-200202050-00005

Pavan, 1987, Normalization of variables of left ventricular function in patients with alcoholic cardiomyopathy after cessation of excessive alcohol intake: an echocardiographic study, Eur Heart J, 8, 535, 10.1093/oxfordjournals.eurheartj.a062314

Bertolet, 1990, Unrecognized left ventricular dysfunction in an apparently healthy cocaine abuse population, Clin Cardiol, 13, 323, 10.1002/clc.4960130505

Chakko, 1995, Cardiac complications of cocaine abuse, Clin Cardiol, 18, 67, 10.1002/clc.4960180206

Moliterno, 1994, Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both, N Engl J Med, 330, 454, 10.1056/NEJM199402173300702

McCord, 2008, Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, Circulation, 117, 1897, 10.1161/CIRCULATIONAHA.107.188950

Marty, 2006, Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy, Ann Oncol, 17, 614, 10.1093/annonc/mdj134

van Dalen, 2008, Cardioprotective interventions for cancer patients receiving anthracyclines, Cochrane Database Syst Rev, 10.1002/14651858.CD003917.pub3

Bovelli, 2010, Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines, Ann Oncol, 21, v277, 10.1093/annonc/mdq200

Martin, 2009, Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations, Oncologist, 14, 1, 10.1634/theoncologist.2008-0137

Figueredo, 2011, Chemical cardiomyopathies: the negative effects of medications and nonprescribed drugs on the heart, Am J Med, 124, 480, 10.1016/j.amjmed.2010.11.031

Dunnick, 2007, Cardiotoxicity of Ma Huang/caffeine or ephedrine/caffeine in a rodent model system, Toxicol Pathol, 35, 657, 10.1080/01926230701459978

Djoenaidi, 1992, Beriberi cardiomyopathy, Eur J Clin Nutr, 46, 227

Retter, 1999, Carnitine and its role in cardiovascular disease, Heart Dis, 1, 108

Khasnis, 2005, Tachycardia-induced cardiomyopathy: a review of literature, Pacing Clin Electrophysiol, 28, 710, 10.1111/j.1540-8159.2005.00143.x

Wilkoff, 2002, Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial, JAMA, 288, 3115, 10.1001/jama.288.24.3115

Wilkoff, 2009, The DAVID (Dual Chamber and VVI Implantable Defibrillator) II trial, J Am Coll Cardiol, 53, 872, 10.1016/j.jacc.2008.10.057

Kindermann, 2012, Update on myocarditis, J Am Coll Cardiol, 59, 779, 10.1016/j.jacc.2011.09.074

McCarthy, 2000, Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis, N Engl J Med, 342, 690, 10.1056/NEJM200003093421003

Elliott, 2008, Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 29, 270, 10.1093/eurheartj/ehm342

Frustaci, 2009, Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study, Eur Heart J, 30, 1995, 10.1093/eurheartj/ehp249

Cooper, 1997, Idiopathic giant-cell myocarditis: natural history and treatment: Multicenter Giant Cell Myocarditis Study Group Investigators, N Engl J Med, 336, 1860, 10.1056/NEJM199706263362603

Cooper, 2008, Usefulness of immunosuppression for giant cell myocarditis, Am J Cardiol, 102, 1535, 10.1016/j.amjcard.2008.07.041

Kaul, 1991, Cardiac manifestations of acquired immune deficiency syndrome: a 1991 update, Am Heart J, 122, 535, 10.1016/0002-8703(91)91013-D

Grody, 1990, Infection of the heart by the human immunodeficiency virus, Am J Cardiol, 66, 203, 10.1016/0002-9149(90)90589-S

Raidel, 2002, Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage, Am J Physiol Heart Circ Physiol, 282, H1672, 10.1152/ajpheart.00955.2001

Barbaro, 1998, Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients: Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS, N Engl J Med, 339, 1093, 10.1056/NEJM199810153391601

Rossi, 1995, The challenge of chagasic cardiomyopathy: the pathologic roles of autonomic abnormalities, autoimmune mechanisms and microvascular changes, and therapeutic implications, Cardiology, 86, 1, 10.1159/000176822

Kounis, 2009, Hypersensitivity myocarditis and hypersensitivity coronary syndrome (Kounis syndrome), Am J Emerg Med, 27, 506, 10.1016/j.ajem.2009.02.025

Leyngold, 2007, Comparison of survival among patients with connective tissue disease and cardiomyopathy (systemic sclerosis, systemic lupus erythematosus, and undifferentiated disease), Am J Cardiol, 100, 513, 10.1016/j.amjcard.2007.03.054

Paradiso, 2001, Evaluation of myocardial involvement in systemic lupus erythematosus by signal-averaged electrocardiography and echocardiography, Acta Cardiol, 56, 381, 10.2143/AC.56.6.2005702

Kazzam, 1991, Non-invasive assessment of systolic left ventricular function in systemic sclerosis, Eur Heart J, 12, 151, 10.1093/oxfordjournals.eurheartj.a059861

Goldenberg, 1992, Symptomatic cardiac involvement in juvenile rheumatoid arthritis, Int J Cardiol, 34, 57, 10.1016/0167-5273(92)90082-E

Gasparyan, 2012, Cardiac complications in rheumatoid arthritis in the absence of occlusive coronary pathology, Rheumatol Int, 32, 461, 10.1007/s00296-009-1318-4

Elkayam, 2001, Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy, N Engl J Med, 344, 1567, 10.1056/NEJM200105243442101

O’Connell, 1986, Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics, J Am Coll Cardiol, 8, 52, 10.1016/S0735-1097(86)80091-2

Murphy, 2010, Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment, J Card Fail, 16, 888, 10.1016/j.cardfail.2010.05.009

Wojcik, 2002, Natural history of C282Y homozygotes for hemochromatosis, Can J Gastroenterol, 16, 297, 10.1155/2002/161569

Gujja, 2010, Iron overload cardiomyopathy: better understanding of an increasing disorder, J Am Coll Cardiol, 56, 1001, 10.1016/j.jacc.2010.03.083

Ronsyn, 2011, Cardiac amyloidosis in full glory, Heart, 97, 720, 10.1136/hrt.2010.215707

Dietrich, 2010, Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement, Blood, 116, 522, 10.1182/blood-2009-11-253237

Palladini, 2010, The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis, Blood, 116, 3426, 10.1182/blood-2010-05-286567

Jacobson, 2011, Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men, Am J Cardiol, 108, 440, 10.1016/j.amjcard.2011.03.069

Srichai, 2011, Cardiac sarcoidosis, J Am Coll Cardiol, 58, 438, 10.1016/j.jacc.2010.10.070

Dubrey, 2010, Diagnosis and management of cardiac sarcoidosis, Prog Cardiovasc Dis, 52, 336, 10.1016/j.pcad.2009.11.010

Kron, 2013, Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis, Europace, 15, 347, 10.1093/europace/eus316

Sharkey, 2010, Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy, J Am Coll Cardiol, 55, 333, 10.1016/j.jacc.2009.08.057

Butman, 1993, Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension, J Am Coll Cardiol, 22, 968, 10.1016/0735-1097(93)90405-P

Drazner, 2001, Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure, N Engl J Med, 345, 574, 10.1056/NEJMoa010641

Drazner, 2008, Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial, Circ Heart Fail, 1, 170, 10.1161/CIRCHEARTFAILURE.108.769778

Stevenson, 1989, The limited reliability of physical signs for estimating hemodynamics in chronic heart failure, JAMA, 261, 884, 10.1001/jama.1989.03420060100040

Anker, 1997, Wasting as independent risk factor for mortality in chronic heart failure, Lancet, 349, 1050, 10.1016/S0140-6736(96)07015-8

Mishkin, 2009, Appropriate evaluation and treatment of heart failure patients after implantable cardioverter-defibrillator discharge: time to go beyond the initial shock, J Am Coll Cardiol, 54, 1993, 10.1016/j.jacc.2009.07.039

Kasai, 2011, Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications, J Am Coll Cardiol, 57, 119, 10.1016/j.jacc.2010.08.627

Setoguchi, 2007, Repeated hospitalizations predict mortality in the community population with heart failure, Am Heart J, 154, 260, 10.1016/j.ahj.2007.01.041

Fonarow, 2008, Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program, J Am Coll Cardiol, 52, 190, 10.1016/j.jacc.2008.03.048

Kittleson, 2003, Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality, J Am Coll Cardiol, 41, 2029, 10.1016/S0735-1097(03)00417-0

Felker, 2006, The Valsalva maneuver: a bedside “biomarker” for heart failure, Am J Med, 119, 117, 10.1016/j.amjmed.2005.06.059

Leier, 2001, Nuggets, pearls, and vignettes of master heart failure clinicians: part 2: the physical examination, Congest Heart Fail, 7, 297, 10.1111/j.1527-5299.2001.01167.x

Aaronson, 1997, Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation, Circulation, 95, 2660, 10.1161/01.CIR.95.12.2660

Fonarow, 2005, Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis, JAMA, 293, 572, 10.1001/jama.293.5.572

Komajda, 2011, Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE), Circ Heart Fail, 4, 27, 10.1161/CIRCHEARTFAILURE.109.932996

Lee, 2003, Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model, JAMA, 290, 2581, 10.1001/jama.290.19.2581

Levy, 2006, The Seattle Heart Failure Model: prediction of survival in heart failure, Circulation, 113, 1424, 10.1161/CIRCULATIONAHA.105.584102

O’Connor, 2008, Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF), Am Heart J, 156, 662, 10.1016/j.ahj.2008.04.030

Peterson, 2010, A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association Get With The Guidelines program, Circ Cardiovasc Qual Outcomes, 3, 25, 10.1161/CIRCOUTCOMES.109.854877

Pocock, 2006, Predictors of mortality and morbidity in patients with chronic heart failure, Eur Heart J, 27, 65, 10.1093/eurheartj/ehi555

Wedel, 2009, Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide, Eur J Heart Fail, 11, 281, 10.1093/eurjhf/hfn046

Lucas, 2000, Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure, Am Heart J, 140, 840, 10.1067/mhj.2000.110933

Amarasingham, 2010, An automated model to identify heart failure patients at risk for 30-day readmission or death using electronic medical record data, Med Care, 48, 981, 10.1097/MLR.0b013e3181ef60d9

The University of Washington. The Seattle Heart Failure Model. Available at: http://depts.washington.edu/shfm/. 2012. Accessed July 11, 2013.

Giamouzis, 2011, Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions, J Card Fail, 17, 54, 10.1016/j.cardfail.2010.08.010

Januzzi, 2006, Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department, Arch Intern Med, 166, 315, 10.1001/archinte.166.3.315

Januzzi, 2010, Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients, Clin Chem, 56, 1814, 10.1373/clinchem.2010.146506

O’Connor, 2010, Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score, J Am Coll Cardiol, 55, 872, 10.1016/j.jacc.2009.08.083

Kociol, 2011, Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims, Circ Heart Fail, 4, 628, 10.1161/CIRCHEARTFAILURE.111.962290

Okonko, 2011, Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival, J Am Coll Cardiol, 58, 1241, 10.1016/j.jacc.2011.04.040

Costello-Boerrigter, 2006, Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction, J Am Coll Cardiol, 47, 345, 10.1016/j.jacc.2005.09.025

de Lemos, 2009, Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study, Am Heart J, 157, 746, 10.1016/j.ahj.2008.12.017

Goetze, 2006, Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction, Eur Heart J, 27, 3004, 10.1093/eurheartj/ehl406

Ng, 2005, Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides, J Am Coll Cardiol, 45, 1043, 10.1016/j.jacc.2004.12.058

Richards, 2001, Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction: Australia-New Zealand Heart Failure Group, J Am Coll Cardiol, 37, 1781, 10.1016/S0735-1097(01)01269-4

Tang, 2003, Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure, Circulation, 108, 2964, 10.1161/01.CIR.0000106903.98196.B6

Vasan, 2002, Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study, JAMA, 288, 1252, 10.1001/jama.288.10.1252

Berger, 2002, B-type natriuretic peptide predicts sudden death in patients with chronic heart failure, Circulation, 105, 2392, 10.1161/01.CIR.0000016642.15031.34

Anand, 2003, Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT), Circulation, 107, 1278, 10.1161/01.CIR.0000054164.99881.00

Forfia, 2005, Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit, J Am Coll Cardiol, 45, 1667, 10.1016/j.jacc.2005.01.046

Taub, 2009, Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation, Heart Fail Clin, 5, 169, 10.1016/j.hfc.2008.11.009

Maeda, 2000, High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure, J Am Coll Cardiol, 36, 1587, 10.1016/S0735-1097(00)00912-8

Neuhold, 2008, Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease, J Am Coll Cardiol, 52, 266, 10.1016/j.jacc.2008.03.050

Januzzi, 2011, Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction, J Am Coll Cardiol, 58, 1881, 10.1016/j.jacc.2011.03.072

Porapakkham, 2010, B-type natriuretic peptide-guided heart failure therapy: a meta-analysis, Arch Intern Med, 170, 507, 10.1001/archinternmed.2010.35

Felker, 2009, Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials, Am Heart J, 158, 422, 10.1016/j.ahj.2009.06.018

Jourdain, 2007, Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study, J Am Coll Cardiol, 49, 1733, 10.1016/j.jacc.2006.10.081

Pfisterer, 2009, BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial, JAMA, 301, 383, 10.1001/jama.2009.2

Berger, 2010, N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: a 3-arm, prospective, randomized pilot study, J Am Coll Cardiol, 55, 645, 10.1016/j.jacc.2009.08.078

Troughton, 2000, Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations, Lancet, 355, 1126, 10.1016/S0140-6736(00)02060-2

Lainchbury, 2009, N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial, J Am Coll Cardiol, 55, 53, 10.1016/j.jacc.2009.02.095

Horwich, 2003, Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure, Circulation, 108, 833, 10.1161/01.CIR.0000084543.79097.34

Sato, 2001, Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes, Circulation, 103, 369, 10.1161/01.CIR.103.3.369

Setsuta, 1999, Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure, Am J Cardiol, 84, 608, 10.1016/S0002-9149(99)00391-4

Hudson, 2004, Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis, Am Heart J, 147, 546, 10.1016/j.ahj.2003.10.014

Tang, 2011, Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival, Am J Cardiol, 108, 385, 10.1016/j.amjcard.2011.03.056

de Boer, 2011, Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction, Ann Med, 43, 60, 10.3109/07853890.2010.538080

Lok, 2010, Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study, Clin Res Cardiol, 99, 323, 10.1007/s00392-010-0125-y

Dao, 2001, Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting, J Am Coll Cardiol, 37, 379, 10.1016/S0735-1097(00)01156-6

Davis, 1994, Plasma brain natriuretic peptide in assessment of acute dyspnoea, Lancet, 343, 440, 10.1016/S0140-6736(94)92690-5

Maisel, 2002, Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure, N Engl J Med, 347, 161, 10.1056/NEJMoa020233

van Kimmenade, 2006, Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure, Am J Cardiol, 98, 386, 10.1016/j.amjcard.2006.02.043

Moe, 2007, N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study, Circulation, 115, 3103, 10.1161/CIRCULATIONAHA.106.666255

Mueller, 2004, Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea, N Engl J Med, 350, 647, 10.1056/NEJMoa031681

Bettencourt, 2004, N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients, Circulation, 110, 2168, 10.1161/01.CIR.0000144310.04433.BE

Cheng, 2001, A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study, J Am Coll Cardiol, 37, 386, 10.1016/S0735-1097(00)01157-8

Fonarow, 2008, Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE, Am J Cardiol, 101, 231, 10.1016/j.amjcard.2007.07.066

Logeart, 2004, Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure, J Am Coll Cardiol, 43, 635, 10.1016/j.jacc.2003.09.044

Maisel, 2004, Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath, J Am Coll Cardiol, 44, 1328, 10.1016/j.jacc.2004.06.015

Zairis, 2010, Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure, Int J Cardiol, 141, 284, 10.1016/j.ijcard.2008.12.017

Peacock, 2008, Cardiac troponin and outcome in acute heart failure, N Engl J Med, 358, 2117, 10.1056/NEJMoa0706824

Lee, 2012, Prediction of heart failure mortality in emergent care: a cohort study, Ann Intern Med, 156, 767, 10.7326/0003-4819-156-11-201206050-00003

Bayes-Genis, 2005, NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality, J Card Fail, 11, S3, 10.1016/j.cardfail.2005.04.006

Dhaliwal, 2009, Reduction in BNP levels with treatment of decompensated heart failure and future clinical events, J Card Fail, 15, 293, 10.1016/j.cardfail.2008.11.007

Alonso-Martinez, 2002, C-reactive protein as a predictor of improvement and readmission in heart failure, Eur J Heart Fail, 4, 331, 10.1016/S1388-9842(02)00021-1

Dieplinger, 2010, Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department, Clin Biochem, 43, 714, 10.1016/j.clinbiochem.2010.02.002

Ilva, 2008, Clinical significance of cardiac troponins I and T in acute heart failure, Eur J Heart Fail, 10, 772, 10.1016/j.ejheart.2008.06.009

Januzzi, 2007, Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study, J Am Coll Cardiol, 50, 607, 10.1016/j.jacc.2007.05.014

Manzano-Fernandez, 2011, Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction, Am J Cardiol, 107, 259, 10.1016/j.amjcard.2010.09.011

Rehman, 2008, Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure, J Am Coll Cardiol, 52, 1458, 10.1016/j.jacc.2008.07.042

Shah, 2010, Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure, Eur J Heart Fail, 12, 826, 10.1093/eurjhf/hfq091

Anwaruddin, 2006, Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study, J Am Coll Cardiol, 47, 91, 10.1016/j.jacc.2005.08.051

Redfield, 2002, Plasma brain natriuretic peptide concentration: impact of age and gender, J Am Coll Cardiol, 40, 976, 10.1016/S0735-1097(02)02059-4

Wang, 2002, Impact of age and sex on plasma natriuretic peptide levels in healthy adults, Am J Cardiol, 90, 254, 10.1016/S0002-9149(02)02464-5

Chang, 2007, Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study, J Am Coll Cardiol, 49, 109, 10.1016/j.jacc.2006.10.040

Frantz, 2005, Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure, Am Heart J, 149, 541, 10.1016/j.ahj.2004.07.036

Tsutamoto, 2001, Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure, J Am Coll Cardiol, 37, 1228, 10.1016/S0735-1097(01)01116-0

Fruhwald, 2007, Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony, Eur Heart J, 28, 1592, 10.1093/eurheartj/ehl505

Januzzi, 2011, Use of biomarkers to “guide” care in chronic heart failure: what have we learned (so far)?, J Card Fail, 17, 622, 10.1016/j.cardfail.2011.06.373

Missov, 1997, Circulating cardiac troponin I in severe congestive heart failure, Circulation, 96, 2953, 10.1161/01.CIR.96.9.2953

Ather, 2011, Recurrent low-level troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure, Int J Cardiol, 301, H2351

Januzzi, 2012, Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section, Eur Heart J, 33, 2265, 10.1093/eurheartj/ehs191

Matsumura, 2006, Long-term prognosis of dilated cardiomyopathy revisited: an improvement in survival over the past 20 years, Circ J, 70, 376, 10.1253/circj.70.376

Deleted in press.

Rizzello, 2009, Prognosis of patients with ischaemic cardiomyopathy after coronary revascularisation: relation to viability and improvement in left ventricular ejection fraction, Heart, 95, 1273, 10.1136/hrt.2008.163972

Allman, 2002, Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis, J Am Coll Cardiol, 39, 1151, 10.1016/S0735-1097(02)01726-6

Beanlands, 2002, Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function, J Am Coll Cardiol, 40, 1735, 10.1016/S0735-1097(02)02489-0

Pagley, 1997, Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability, Circulation, 96, 793, 10.1161/01.CIR.96.3.793

Senior, 1999, Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure, J Am Coll Cardiol, 33, 1848, 10.1016/S0735-1097(99)00102-3

Kwon, 2009, Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study, JACC Cardiovasc Imaging, 2, 34, 10.1016/j.jcmg.2008.09.010

Ordovas, 2011, Delayed contrast enhancement on MR images of myocardium: past, present, future, Radiology, 261, 358, 10.1148/radiol.11091882

Syed, 2010, Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis, JACC Cardiovasc Imaging, 3, 155, 10.1016/j.jcmg.2009.09.023

Beller, 2012, Tests that may be overused or misused in cardiology: the Choosing Wisely campaign, J Nucl Cardiol, 19, 401, 10.1007/s12350-012-9569-y

Douglas, 2011, J Am Coll Cardiol, 57, 1126, 10.1016/j.jacc.2010.11.002

Agha, 2009, Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers, J Card Fail, 15, 586, 10.1016/j.cardfail.2009.03.002

Aurigemma, 2001, Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study, J Am Coll Cardiol, 37, 1042, 10.1016/S0735-1097(01)01110-X

Chen, 2006, NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy, Eur Heart J, 27, 839, 10.1093/eurheartj/ehi811

Gardin, 2001, M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study), Am J Cardiol, 87, 1051, 10.1016/S0002-9149(01)01460-6

Grayburn, 2005, Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the Beta-blocker Evaluation of Survival Trial (BEST), J Am Coll Cardiol, 45, 1064, 10.1016/j.jacc.2004.12.069

Francis, 1995, Open access echocardiography in management of heart failure in the community, BMJ, 310, 634, 10.1136/bmj.310.6980.634

Bonow, 2005, J Am Coll Cardiol, 46, 1144, 10.1016/j.jacc.2005.07.012

Valle-Munoz, 2009, Late gadolinium enhancement-cardiovascular magnetic resonance identifies coronary artery disease as the aetiology of left ventricular dysfunction in acute new-onset congestive heart failure, Eur J Echocardiogr, 10, 968, 10.1093/ejechocard/jep115

Butler, 2007, The emerging role of multi-detector computed tomography in heart failure, J Card Fail, 13, 215, 10.1016/j.cardfail.2006.11.014

van Royen, 1996, Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions, Am J Cardiol, 77, 843, 10.1016/S0002-9149(97)89179-5

Atchley, 2009, Am Heart J, 158, S53, 10.1016/j.ahj.2009.07.009

Nichols, 2010, Automated detection of left ventricular dyskinesis by gated blood pool SPECT, Nucl Med Commun, 31, 881, 10.1097/MNM.0b013e32833d82ff

Soman, 2009, Etiology and pathophysiology of new-onset heart failure: evaluation by myocardial perfusion imaging, J Nucl Cardiol, 16, 82, 10.1007/s12350-008-9010-8

Bonow, 2011, Myocardial viability and survival in ischemic left ventricular dysfunction, N Engl J Med, 364, 1617, 10.1056/NEJMoa1100358

Binanay, 2005, Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial, JAMA, 294, 1625, 10.1001/jama.294.13.1625

Shah, 2005, Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials, JAMA, 294, 1664, 10.1001/jama.294.13.1664

Alderman, 1983, Results of coronary artery surgery in patients with poor left ventricular function (CASS), Circulation, 68, 785, 10.1161/01.CIR.68.4.785

Patel, 2009, J Am Coll Cardiol, 53, 530, 10.1016/j.jacc.2008.10.005

Velazquez, 2011, Coronary-artery bypass surgery in patients with left ventricular dysfunction, N Engl J Med, 364, 1607, 10.1056/NEJMoa1100356

Cooper, 2007, The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology, Circulation, 116, 2216, 10.1161/CIRCULATIONAHA.107.186093

Beckett, 2008, Treatment of hypertension in patients 80 years of age or older, N Engl J Med, 358, 1887, 10.1056/NEJMoa0801369

Sciarretta, 2011, Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk, Arch Intern Med, 171, 384, 10.1001/archinternmed.2010.427

Staessen, 2003, Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003, J Hypertens, 21, 1055, 10.1097/00004872-200306000-00002

Verdecchia, 2009, Circulation, 120, 1380, 10.1161/CIRCULATIONAHA.109.865774

Mills, 2008, Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients, J Am Coll Cardiol, 52, 1769, 10.1016/j.jacc.2008.08.039

Taylor, 2011, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev

Braunwald, 2004, Angiotensin-converting-enzyme inhibition in stable coronary artery disease, N Engl J Med, 351, 2058, 10.1056/NEJMoa042739

Kenchaiah, 2009, Body mass index and vigorous physical activity and the risk of heart failure among men, Circulation, 119, 44, 10.1161/CIRCULATIONAHA.108.807289

Lee, 2007, Antecedent blood pressure, body mass index, and the risk of incident heart failure in later life, Hypertension, 50, 869, 10.1161/HYPERTENSIONAHA.107.095380

Butler, 2008, Incident heart failure prediction in the elderly: the Health ABC heart failure score, Circ Heart Fail, 1, 125, 10.1161/CIRCHEARTFAILURE.108.768457

Kalogeropoulos, 2009, Glycemic status and incident heart failure in elderly without history of diabetes mellitus: the Health, Aging, and Body Composition study, J Card Fail, 15, 593, 10.1016/j.cardfail.2009.03.001

Lind, 2011, Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study, Lancet, 378, 140, 10.1016/S0140-6736(11)60471-6

Pfister, 2013, A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study, Int J Cardiol, 162, 112, 10.1016/j.ijcard.2011.05.056

Bibbins-Domingo, 2004, Predictors of heart failure among women with coronary disease, Circulation, 110, 1424, 10.1161/01.CIR.0000141726.01302.83

1997, Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria, Lancet, 349, 1787, 10.1016/S0140-6736(96)10244-0

Coyle, 2004, The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus, Ann Pharmacother, 38, 1731, 10.1345/aph.1E182

Berl, 2003, Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy, Ann Intern Med, 138, 542, 10.7326/0003-4819-138-7-200304010-00010

Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161

Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301

Choueiri, 2011, Congestive heart failure risk in patients with breast cancer treated with bevacizumab, J Clin Oncol, 29, 632, 10.1200/JCO.2010.31.9129

Du, 2011, Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005, Med Oncol, 28, S80, 10.1007/s12032-010-9717-7

Yusuf, 2011, Chemotherapy-induced cardiomyopathy, Expert Rev Cardiovasc Ther, 9, 231, 10.1586/erc.10.188

Sawaya, 2011, Early detection and prediction of cardiotoxicity in chemotherapy-treated patients, Am J Cardiol, 107, 1375, 10.1016/j.amjcard.2011.01.006

Kalogeropoulos, 2009, Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study, Arch Intern Med, 169, 708, 10.1001/archinternmed.2009.40

McKie, 2010, The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects, J Am Coll Cardiol, 55, 2140, 10.1016/j.jacc.2010.01.031

Velagaleti, 2010, Multimarker approach for the prediction of heart failure incidence in the community, Circulation, 122, 1700, 10.1161/CIRCULATIONAHA.109.929661

deFilippi, 2010, Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults, JAMA, 304, 2494, 10.1001/jama.2010.1708

Blecker, 2011, High-normal albuminuria and risk of heart failure in the community, Am J Kidney Dis, 58, 47, 10.1053/j.ajkd.2011.02.391

Dhingra, 2011, Chronic kidney disease and the risk of heart failure in men, Circ Heart Fail, 4, 138, 10.1161/CIRCHEARTFAILURE.109.899070

Dhingra, 2010, Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community, Eur J Heart Fail, 12, 812, 10.1093/eurjhf/hfq106

Heidenreich, 2004, Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction, J Am Coll Cardiol, 43, 1019, 10.1016/j.jacc.2003.10.043

Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial: the SAVE Investigators, N Engl J Med, 327, 669, 10.1056/NEJM199209033271001

1987, Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N Engl J Med, 316, 1429, 10.1056/NEJM198706043162301

1992, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, N Engl J Med, 327, 685, 10.1056/NEJM199209033271003

Pfeffer, 2003, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, N Engl J Med, 349, 1893, 10.1056/NEJMoa032292

Dargie, 2001, Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial, Lancet, 357, 1385, 10.1016/S0140-6736(00)04560-8

Vantrimpont, 1997, Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study: SAVE Investigators, J Am Coll Cardiol, 29, 229, 10.1016/S0735-1097(96)00489-5

Exner, 1999, Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction, J Am Coll Cardiol, 33, 916, 10.1016/S0735-1097(98)00675-5

Scirica, 2006, Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study, J Am Coll Cardiol, 47, 2326, 10.1016/j.jacc.2006.03.034

Afilalo, 2007, Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials, Heart, 93, 914, 10.1136/hrt.2006.112508

Ho, 2012, Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study), Am J Cardiol, 109, 1761, 10.1016/j.amjcard.2012.02.019

Strandberg, 2009, Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction, Am J Cardiol, 103, 1381, 10.1016/j.amjcard.2009.01.377

Kjekshus, 1997, The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease, J Card Fail, 3, 249, 10.1016/S1071-9164(97)90022-1

Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401

Moss, 2002, Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N Engl J Med, 346, 877, 10.1056/NEJMoa013474

de Lemos, 2004, Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial, JAMA, 292, 1307, 10.1001/jama.292.11.1307

Dahlof, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods: the LIFE Study Group, Am J Hypertens, 10, 705, 10.1016/S0895-7061(97)88956-X

Mancia, 2010, Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Circulation, 122, 847, 10.1161/CIRCULATIONAHA.110.960120

2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, 2981, 10.1001/jama.288.23.2981

Staessen, 2001, Cardiovascular protection and blood pressure reduction: a meta-analysis, Lancet, 358, 1305, 10.1016/S0140-6736(01)06411-X

Pitt, 2003, Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study, Circulation, 108, 1831, 10.1161/01.CIR.0000091405.00772.6E

Moss, 1996, Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial Investigators, N Engl J Med, 335, 1933, 10.1056/NEJM199612263352601

Boren, 2009, Heart failure self-management education: a systematic review of the evidence, Int J Evid Based Healthc, 7, 159, 10.1111/j.1744-1609.2009.00134.x

Gwadry-Sridhar, 2005, Pilot study to determine the impact of a multidisciplinary educational intervention in patients hospitalized with heart failure, Am Heart J, 150, 982, 10.1016/j.ahj.2005.08.016

Koelling, 2005, Discharge education improves clinical outcomes in patients with chronic heart failure, Circulation, 111, 179, 10.1161/01.CIR.0000151811.53450.B8

VanSuch, 2006, Effect of discharge instructions on readmission of hospitalised patients with heart failure: do all of the Joint Commission on Accreditation of Healthcare Organizations heart failure core measures reflect better care?, Qual Saf Health Care, 15, 414, 10.1136/qshc.2005.017640

Aguado, 2010, Long-term implications of a single home-based educational intervention in patients with heart failure, Heart Lung, 39, S14, 10.1016/j.hrtlng.2010.04.010

Riegel, 2009, State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association, Circulation, 120, 1141, 10.1161/CIRCULATIONAHA.109.192628

Powell, 2010, Self-management counseling in patients with heart failure: the Heart Failure Adherence and Retention Randomized Behavioral Trial, JAMA, 304, 1331, 10.1001/jama.2010.1362

Jha, 2009, Public reporting of discharge planning and rates of readmissions, N Engl J Med, 361, 2637, 10.1056/NEJMsa0904859

Gallager, 2011, Social support and self-care in heart failure, J Cardiovasc Nurs, 26, 439, 10.1097/JCN.0b013e31820984e1

Luttik, 2005, The importance and impact of social support on outcomes in patients with heart failure: an overview of the literature, J Cardiovasc Nurs, 20, 162, 10.1097/00005082-200505000-00007

Struthers, 2000, Social deprivation increases cardiac hospitalisations in chronic heart failure independent of disease severity and diuretic non-adherence, Heart, 83, 12, 10.1136/heart.83.1.12

Murberg, 2001, Social relationships and mortality in patients with congestive heart failure, J Psychosom Res, 51, 521, 10.1016/S0022-3999(01)00226-4

Murberg, 2004, Long-term effect of social relationships on mortality in patients with congestive heart failure, Int J Psychiatry Med, 34, 207, 10.2190/GKJ2-P8BD-V59X-MJNQ

Dickstein, 2008, Eur Heart J, 29, 2388, 10.1093/eurheartj/ehn309

Malcom, 2008, Canadian Cardiovascular Society Consensus Conference guidelines on heart failure–2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies, Can J Cardiol, 24, 21, 10.1016/S0828-282X(08)70545-2

Lennie, 2011, Three gram sodium intake is associated with longer event-free survival only in patients with advanced heart failure, J Card Fail, 17, 325, 10.1016/j.cardfail.2010.11.008

Arcand, 2011, A high-sodium diet is associated with acute decompensated heart failure in ambulatory heart failure patients: a prospective follow-up study, Am J Clin Nutr, 93, 332, 10.3945/ajcn.110.000174

Cody, 1986, Sodium and water balance in chronic congestive heart failure, J Clin Invest, 77, 1441, 10.1172/JCI112456

Damgaard, 2006, Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure, Am J Physiol Regul Integr Comp Physiol, 290, R1294, 10.1152/ajpregu.00738.2005

Volpe, 1997, Intrarenal determinants of sodium retention in mild heart failure: effects of angiotensin-converting enzyme inhibition, Hypertension, 30, 168, 10.1161/01.HYP.30.2.168

Volpe, 1993, Abnormalities of sodium handling and of cardiovascular adaptations during high salt diet in patients with mild heart failure, Circulation, 88, 1620, 10.1161/01.CIR.88.4.1620

Paterna, 2009, Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure, Am J Cardiol, 103, 93, 10.1016/j.amjcard.2008.08.043

Paterna, 2008, Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?, Clin Sci (Lond), 114, 221, 10.1042/CS20070193

Parrinello, 2009, Long-term effects of dietary sodium intake on cytokines and neurohormonal activation in patients with recently compensated congestive heart failure, J Card Fail, 15, 864, 10.1016/j.cardfail.2009.06.002

He, 2004, Effect of longer-term modest salt reduction on blood pressure, Cochrane Database Syst Rev, 10.1002/14651858.CD004937

1997, Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, phase II, Arch Intern Med, 157, 657, 10.1001/archinte.1997.00440270105009

Jula, 1994, Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mild-to-moderate essential hypertension, Circulation, 89, 1023, 10.1161/01.CIR.89.3.1023

Cook, 2007, Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the Trials of Hypertension Prevention (TOHP), BMJ, 334, 885, 10.1136/bmj.39147.604896.55

Strazzullo, 2009, Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies, BMJ, 339, b4567, 10.1136/bmj.b4567

Gupta, 2012, Dietary sodium intake in heart failure, Circulation, 126, 479, 10.1161/CIRCULATIONAHA.111.062430

Arzt, 2007, Circulation, 115, 3173, 10.1161/CIRCULATIONAHA.106.683482

Bradley, 2005, Continuous positive airway pressure for central sleep apnea and heart failure, N Engl J Med, 353, 2025, 10.1056/NEJMoa051001

Kaneko, 2003, Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea, N Engl J Med, 348, 1233, 10.1056/NEJMoa022479

Mansfield, 2004, Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure, Am J Respir Crit Care Med, 169, 361, 10.1164/rccm.200306-752OC

MacDonald, 2008, The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers, J Clin Sleep Med, 4, 38, 10.5664/jcsm.27076

Arzt, 2006, Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea, Arch Intern Med, 166, 1716, 10.1001/archinte.166.16.1716

Pasini, 2004, Inadequate nutritional intake for daily life activity of clinically stable patients with chronic heart failure, Am J Cardiol, 93, 41A, 10.1016/j.amjcard.2003.11.009

Habbu, 2006, The obesity paradox: fact or fiction?, Am J Cardiol, 98, 944, 10.1016/j.amjcard.2006.04.039

Alpert, 1995, Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss, Am J Cardiol, 76, 1194, 10.1016/S0002-9149(99)80338-5

Ristow, 2008, Improvement in dilated cardiomyopathy after bariatric surgery, J Card Fail, 14, 198, 10.1016/j.cardfail.2007.12.006

Sayin, 2005, Sibutramine: possible cause of a reversible cardiomyopathy, Int J Cardiol, 99, 481, 10.1016/j.ijcard.2003.11.060

Davies, 2010, Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis, Eur J Heart Fail, 12, 706, 10.1093/eurjhf/hfq056

McKelvie, 2008, Exercise training in patients with heart failure: clinical outcomes, safety, and indications, Heart Fail Rev, 13, 3, 10.1007/s10741-007-9052-z

O’Connor, 2009, Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial, JAMA, 301, 1439, 10.1001/jama.2009.454

Pina, 2003, Exercise and heart failure: a statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention, Circulation, 107, 1210, 10.1161/01.CIR.0000055013.92097.40

Smart, 2004, Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity, Am J Med, 116, 693, 10.1016/j.amjmed.2003.11.033

Piepoli, 2004, Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH), BMJ, 328, 189, 10.1136/bmj.328.7441.711-b

Austin, 2005, Randomised controlled trial of cardiac rehabilitation in elderly patients with heart failure, Eur J Heart Fail, 7, 411, 10.1016/j.ejheart.2004.10.004

Austin, 2008, Five-year follow-up findings from a randomized controlled trial of cardiac rehabilitation for heart failure, Eur J Cardiovasc Prev Rehabil, 15, 162, 10.1097/HJR.0b013e3282f10e87

Cohn, 1991, A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure, N Engl J Med, 325, 303, 10.1056/NEJM199108013250502

1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501

Garg, 1995, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials, JAMA, 273, 1450, 10.1001/jama.1995.03520420066040

Maggioni, 2002, Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors, J Am Coll Cardiol, 40, 1414, 10.1016/S0735-1097(02)02304-5

1990, Xamoterol in severe heart failure, Lancet, 336, 1, 10.1016/0140-6736(90)91517-E

1995, Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease, Circulation, 92, 212, 10.1161/01.CIR.92.2.212

2001, A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure, N Engl J Med, 344, 1659, 10.1056/NEJM200105313442202

Poole-Wilson, 2003, Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial, Lancet, 362, 7, 10.1016/S0140-6736(03)13800-7

Pfeffer, 2003, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme, Lancet, 362, 759, 10.1016/S0140-6736(03)14282-1

Konstam, 2009, Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial, Lancet, 374, 1840, 10.1016/S0140-6736(09)61913-9

Pitt, 1997, Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE), Lancet, 349, 747, 10.1016/S0140-6736(97)01187-2

Carson, 1999, Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials, J Card Fail, 5, 178, 10.1016/S1071-9164(99)90001-5

Taylor, 2004, Combination of isosorbide dinitrate and hydralazine in blacks with heart failure, N Engl J Med, 351, 2049, 10.1056/NEJMoa042934

Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001

Zannad, 2011, Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, 364, 11, 10.1056/NEJMoa1009492

Brater, 1998, Diuretic therapy, N Engl J Med, 339, 387, 10.1056/NEJM199808063390607

Cody, 1994, Diuretic treatment for the sodium retention of congestive heart failure, Arch Intern Med, 154, 1905, 10.1001/archinte.1994.00420170045004

Patterson, 1994, Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion: Torsemide Investigators Group, Pharmacotherapy, 14, 514, 10.1002/j.1875-9114.1994.tb02848.x

Sherman, 1986, Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure, Clin Pharmacol Ther, 40, 587, 10.1038/clpt.1986.228

Wilson, 1981, Effect of diuresis on the performance of the failing left ventricle in man, Am J Med, 70, 234, 10.1016/0002-9343(81)90755-5

Parker, 1993, The effects of oral ibopamine in patients with mild heart failure: a double blind placebo controlled comparison to furosemide: the Ibopamine Study Group, Int J Cardiol, 40, 221, 10.1016/0167-5273(93)90004-Z

Richardson, 1987, Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure, Lancet, 2, 709, 10.1016/S0140-6736(87)91074-9

Risler, 1994, Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure, Cardiology, 84, 155, 10.1159/000176468

Vargo, 1995, Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure, Clin Pharmacol Ther, 57, 601, 10.1016/0009-9236(95)90222-8

Herchuelz, 1989, Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance, J Pharmacol Exp Ther, 248, 1175

Gottlieb, 1992, Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy, Am J Cardiol, 70, 890, 10.1016/0002-9149(92)90733-F

Brater, 2001, Renal effects of COX-2-selective inhibitors, Am J Nephrol, 21, 1, 10.1159/000046212

Dormans, 1996, Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion, J Am Coll Cardiol, 28, 376, 10.1016/0735-1097(96)00161-1

Oster, 1983, Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention, Ann Intern Med, 99, 405, 10.7326/0003-4819-99-3-405

Ellison, 1991, The physiologic basis of diuretic synergism: its role in treating diuretic resistance, Ann Intern Med, 114, 886, 10.7326/0003-4819-114-10-886

Sica, 1996, Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships, Clin Pharmacokinet, 30, 229, 10.2165/00003088-199630030-00004

Epstein, 1977, Potentiation of furosemide by metolazone in refractory edema, Curr Ther Res, 656

Steiness, 1976, Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy, Br Heart J, 38, 167, 10.1136/hrt.38.2.167

Packer, 1999, Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure, Circulation, 100, 2312, 10.1161/01.CIR.100.23.2312

Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207

Packer, 2001, Effect of carvedilol on survival in severe chronic heart failure, N Engl J Med, 344, 1651, 10.1056/NEJM200105313442201

1999, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2

Cohn, 1986, Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study, N Engl J Med, 314, 1547, 10.1056/NEJM198606123142404

Granger, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial, Lancet, 362, 772, 10.1016/S0140-6736(03)14284-5

Crozier, 1995, Losartan in heart failure: hemodynamic effects and tolerability, Circulation, 91, 691, 10.1161/01.CIR.91.3.691

Gottlieb, 1993, Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure, Circulation, 88, 1602, 10.1161/01.CIR.88.4.1602

Mazayev, 1998, Valsartan in heart failure patients previously untreated with an ACE inhibitor, Int J Cardiol, 65, 239, 10.1016/S0167-5273(98)00149-1

McKelvie, 1999, Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: the RESOLVD Pilot Study Investigators, Circulation, 100, 1056, 10.1161/01.CIR.100.10.1056

Riegger, 1999, Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil, Circulation, 100, 2224, 10.1161/01.CIR.100.22.2224

Sharma, 2000, Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure: Losartan Heart Failure Mortality Meta-analysis Study Group, Am J Cardiol, 85, 187, 10.1016/S0002-9149(99)00646-3

Velazquez, 2003, VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context, Eur J Heart Fail, 5, 537, 10.1016/S1388-9842(03)00112-0

Cicardi, 2004, Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment, Arch Intern Med, 164, 910, 10.1001/archinte.164.8.910

Makani, 2012, Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors, Am J Cardiol, 110, 383, 10.1016/j.amjcard.2012.03.034

Toh, 2012, Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system, Arch Intern Med, 172, 1582, 10.1001/2013.jamainternmed.34

Warner, 2000, Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema, Ann Pharmacother, 34, 526, 10.1345/aph.19294

Fisher, 1994, Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial, J Am Coll Cardiol, 23, 943, 10.1016/0735-1097(94)90641-6

Metra, 1994, Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy, J Am Coll Cardiol, 24, 1678, 10.1016/0735-1097(94)90174-0

Olsen, 1995, Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study, J Am Coll Cardiol, 25, 1225, 10.1016/0735-1097(95)00012-S

Krum, 1995, Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure, Circulation, 92, 1499, 10.1161/01.CIR.92.6.1499

Waagstein, 1993, Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group, Lancet, 342, 1441, 10.1016/0140-6736(93)92930-R

1994, A randomized trial of beta-blockade in heart failure, Circulation, 90, 1765

Packer, 1996, Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial: Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise, Circulation, 94, 2793, 10.1161/01.CIR.94.11.2793

Colucci, 1996, Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure: US Carvedilol Heart Failure Study Group, Circulation, 94, 2800, 10.1161/01.CIR.94.11.2800

Packer, 1996, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group, N Engl J Med, 334, 1349, 10.1056/NEJM199605233342101

1997, Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease, Lancet, 349, 375, 10.1016/S0140-6736(97)80008-6

van Veldhuisen, 2009, Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure), J Am Coll Cardiol, 53, 2150, 10.1016/j.jacc.2009.02.046

1998, Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison, Eur Heart J, 19, 481, 10.1053/euhj.1997.0839

Epstein, 1966, The effect of beta adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease, Ann Intern Med, 65, 20, 10.7326/0003-4819-65-1-20

Weil, 1968, Plasma volume expansion resulting from interference with adrenergic function in normal man, Circulation, 37, 54, 10.1161/01.CIR.37.1.54

Gattis, 2004, Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial, J Am Coll Cardiol, 43, 1534, 10.1016/j.jacc.2003.12.040

Waagstein, 1989, Long-term beta-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol, Circulation, 80, 551, 10.1161/01.CIR.80.3.551

Vizzardi, 2010, Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure, Am J Cardiol, 106, 1292, 10.1016/j.amjcard.2010.06.052

Juurlink, 2004, Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study, N Engl J Med, 351, 543, 10.1056/NEJMoa040135

Bozkurt, 2003, Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines, J Am Coll Cardiol, 41, 211, 10.1016/S0735-1097(02)02694-3

Butler, 2012, Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction: Heart Failure Society of America Guidelines Committee, J Card Fail, 18, 265, 10.1016/j.cardfail.2012.02.005

Fonarow, 1992, Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial, J Am Coll Cardiol, 19, 842, 10.1016/0735-1097(92)90529-V

Fonarow, 2011, Potential impact of optimal implementation of evidence-based heart failure therapies on mortality, Am Heart J, 161, 1024, 10.1016/j.ahj.2011.01.027

1997, The effect of digoxin on mortality and morbidity in patients with heart failure, N Engl J Med, 336, 525, 10.1056/NEJM199702203360801

1988, Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure, JAMA, 259, 539, 10.1001/jama.1988.03720040031022

Dobbs, 1977, Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients, Br Med J, 1, 749, 10.1136/bmj.1.6063.749

Lee, 1982, Heart failure in outpatients: a randomized trial of digoxin versus placebo, N Engl J Med, 306, 699, 10.1056/NEJM198203253061202

Guyatt, 1988, A controlled trial of digoxin in congestive heart failure, Am J Cardiol, 61, 371, 10.1016/0002-9149(88)90947-2

DiBianco, 1989, A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure, N Engl J Med, 320, 677, 10.1056/NEJM198903163201101

Uretsky, 1993, Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial: PROVED Investigative Group, J Am Coll Cardiol, 22, 955, 10.1016/0735-1097(93)90403-N

Packer, 1993, Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors: RADIANCE Study, N Engl J Med, 329, 1, 10.1056/NEJM199307013290101

Matsuda, 1991, Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation, Cardiovasc Res, 25, 453, 10.1093/cvr/25.6.453

David, 1979, Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent, Am J Cardiol, 44, 1378, 10.1016/0002-9149(79)90456-9

Farshi, 1999, Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens, J Am Coll Cardiol, 33, 304, 10.1016/S0735-1097(98)00561-0

Khand, 2003, Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?, J Am Coll Cardiol, 42, 1944, 10.1016/j.jacc.2003.07.020

Jelliffe, 1974, A nomogram for digoxin therapy, Am J Med, 57, 63, 10.1016/0002-9343(74)90769-4

Rathore, 2003, Association of serum digoxin concentration and outcomes in patients with heart failure, JAMA, 289, 871, 10.1001/jama.289.7.871

Adams, 2005, Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group trial: a retrospective analysis, J Am Coll Cardiol, 46, 497, 10.1016/j.jacc.2005.02.091

Steiner, 1994, Incidence of digoxin toxicity in outpatients, West J Med, 161, 474

Arnold, 1980, Long-term digitalis therapy improves left ventricular function in heart failure, N Engl J Med, 303, 1443, 10.1056/NEJM198012183032503

Gheorghiade, 1995, Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors, Circulation, 92, 1801, 10.1161/01.CIR.92.7.1801

Slatton, 1997, Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm?, J Am Coll Cardiol, 29, 1206, 10.1016/S0735-1097(97)00057-0

Fogelman, 1971, Fallibility of plasma-digoxin in differentiating toxic from non-toxic patients, Lancet, 2, 727, 10.1016/S0140-6736(71)92100-3

Ingelfinger, 1976, The serum digitalis concentration: does it diagnose digitalis toxicity?, N Engl J Med, 294, 867, 10.1056/NEJM197604152941603

Juurlink, 2003, Drug-drug interactions among elderly patients hospitalized for drug toxicity, JAMA, 289, 1652, 10.1001/jama.289.13.1652

Hager, 1979, Digoxin-quinidine interaction: pharmacokinetic evaluation, N Engl J Med, 300, 1238, 10.1056/NEJM197905313002202

Bizjak, 1997, Digoxin-macrolide drug interaction, Ann Pharmacother, 31, 1077, 10.1177/106002809703100918

Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039

Cairns, 2011, Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter, Can J Cardiol, 27, 74, 10.1016/j.cjca.2010.11.007

1994, Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials, Arch Intern Med, 154, 1449, 10.1001/archinte.1994.00420130036007

Hughes, 2008, Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data, Thromb Haemost, 99, 295, 10.1160/TH07-08-0508

Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561

Connolly, 2010, Newly identified events in the RE-LY trial, N Engl J Med, 363, 1875, 10.1056/NEJMc1007378

Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638

Dries, 1997, Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials, J Am Coll Cardiol, 29, 1074, 10.1016/S0735-1097(97)00019-3

Camm, 2010, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur Heart J, 31, 2369, 10.1093/eurheartj/ehq278

Freudenberger, 2007, Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), Circulation, 115, 2637, 10.1161/CIRCULATIONAHA.106.661397

Loh, 1997, Ventricular dysfunction and the risk of stroke after myocardial infarction, N Engl J Med, 336, 251, 10.1056/NEJM199701233360403

Massie, 2009, Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial, Circulation, 119, 1616, 10.1161/CIRCULATIONAHA.108.801753

Homma, 2012, Warfarin and aspirin in patients with heart failure and sinus rhythm, N Engl J Med, 366, 1859, 10.1056/NEJMoa1202299

Fuster, 1981, The natural history of idiopathic dilated cardiomyopathy, Am J Cardiol, 47, 525, 10.1016/0002-9149(81)90534-8

Stratton, 1988, Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy, Circulation, 78, 1388, 10.1161/01.CIR.78.6.1388

Jafri, 1997, Hypercoagulability in heart failure, Semin Thromb Hemost, 23, 543, 10.1055/s-2007-996133

Dunkman, 1993, Incidence of thromboembolic events in congestive heart failure: the V-HeFT VA Cooperative Studies Group, Circulation, 87, VI94

Dunkman, 1995, Thromboembolism and antithrombotic therapy in congestive heart failure, J Cardiovasc Risk, 2, 107, 10.1097/00043798-199504000-00005

Cioffi, 1996, Systemic thromboembolism in chronic heart failure: a prospective study in 406 patients, Eur Heart J, 17, 1381, 10.1093/oxfordjournals.eurheartj.a015073

Baker, 1994, Management of heart failure, IV: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction, JAMA, 272, 1614, 10.1001/jama.1994.03520200070038

Katz, 1995, Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: can clinical factors identify patients at increased risk?, J Cardiovasc Risk, 2, 97, 10.1097/00043798-199504000-00003

Al-Khadra, 1998, Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction, J Am Coll Cardiol, 31, 749, 10.1016/S0735-1097(98)00006-0

Dries, 1997, Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure, Am J Cardiol, 79, 909, 10.1016/S0002-9149(97)00013-1

Lip, 2010, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation, Chest, 137, 263, 10.1378/chest.09-1584

Lip, 2001, Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm, Cochrane Database Syst Rev, CD003333

Horwich, 2004, Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure, J Am Coll Cardiol, 43, 642, 10.1016/j.jacc.2003.07.049

Anker, 2006, Statin use and survival in patients with chronic heart failure: results from two observational studies with 5200 patients, Int J Cardiol, 112, 234, 10.1016/j.ijcard.2006.03.057

Go, 2006, Statin therapy and risks for death and hospitalization in chronic heart failure, JAMA, 296, 2105, 10.1001/jama.296.17.2105

Foody, 2006, Statins and mortality among elderly patients hospitalized with heart failure, Circulation, 113, 1086, 10.1161/CIRCULATIONAHA.105.591446

Kjekshus, 2007, Rosuvastatin in older patients with systolic heart failure, N Engl J Med, 357, 2248, 10.1056/NEJMoa0706201

Tavazzi, 2008, Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1231, 10.1016/S0140-6736(08)61240-4

Macchia, 2005, Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids, Eur J Heart Fail, 7, 904, 10.1016/j.ejheart.2005.04.008

Tavazzi, 2008, Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1223, 10.1016/S0140-6736(08)61239-8

Lavie, 2009, Omega-3 polyunsaturated fatty acids and cardiovascular diseases, J Am Coll Cardiol, 54, 585, 10.1016/j.jacc.2009.02.084

1999, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial, Lancet, 354, 447, 10.1016/S0140-6736(99)07072-5

Nodari, 2011, Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy, J Am Coll Cardiol, 57, 870, 10.1016/j.jacc.2010.11.017

McMurray, 2010, Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure), J Am Coll Cardiol, 56, 1196, 10.1016/j.jacc.2010.02.075

Soukoulis, 2009, Micronutrient deficiencies an unmet need in heart failure, J Am Coll Cardiol, 54, 1660, 10.1016/j.jacc.2009.08.012

1990, Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II), Am J Cardiol, 66, 779, 10.1016/0002-9149(90)90351-Z

Goldstein, 1991, Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction: the Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group, Circulation, 83, 52, 10.1161/01.CIR.83.1.52

Waldo, 1996, Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: the SWORD Investigators: Survival With Oral d-Sotalol, Lancet, 348, 7, 10.1016/S0140-6736(96)02149-6

Kober, 2008, Increased mortality after dronedarone therapy for severe heart failure, N Engl J Med, 358, 2678, 10.1056/NEJMoa0800456

1989, Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction, N Engl J Med, 321, 406, 10.1056/NEJM198908103210629

1988, The effect of diltiazem on mortality and reinfarction after myocardial infarction, N Engl J Med, 319, 385, 10.1056/NEJM198808183190701

Figulla, 1996, Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy: results of the Diltiazem in Dilated Cardiomyopathy Trial, Circulation, 94, 346, 10.1161/01.CIR.94.3.346

Elkayam, 1990, A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure, Circulation, 82, 1954, 10.1161/01.CIR.82.6.1954

Gislason, 2009, Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure, Arch Intern Med, 169, 141, 10.1001/archinternmed.2008.525

Heerdink, 1998, NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics, Arch Intern Med, 158, 1108, 10.1001/archinte.158.10.1108

Hudson, 2005, Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study, BMJ, 330, 1370, 10.1136/bmj.330.7504.1370

Lipscombe, 2007, Thiazolidinediones and cardiovascular outcomes in older patients with diabetes, JAMA, 298, 2634, 10.1001/jama.298.22.2634

Azuma, 1992, Usefulness of taurine in chronic congestive heart failure and its prospective application, Jpn Circ J, 56, 95, 10.1253/jcj.56.95

Fazio, 1996, A preliminary study of growth hormone in the treatment of dilated cardiomyopathy, N Engl J Med, 334, 809, 10.1056/NEJM199603283341301

Ferrari, 1997, The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure, J Card Fail, 3, 217, 10.1016/S1071-9164(97)90018-X

Ghatak, 1996, Oxy free radical system in heart failure and therapeutic role of oral vitamin E, Int J Cardiol, 57, 119, 10.1016/S0167-5273(96)02787-8

Hamilton, 1996, Thyroid hormone abnormalities in heart failure: possibilities for therapy, Thyroid, 6, 527, 10.1089/thy.1996.6.527

Soja, 1997, Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials, Mol Aspects Med, S159, 10.1016/S0098-2997(97)00042-3

Toma, 2012, Testosterone supplementation in heart failure: a meta-analysis, Circ Heart Fail, 5, 315, 10.1161/CIRCHEARTFAILURE.111.965632

Morris, 2003, Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force, Ann Intern Med, 139, 56, 10.7326/0003-4819-139-1-200307010-00014

Hofman-Bang, 1995, Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure: the Q10 Study Group, J Card Fail, 1, 101, 10.1016/1071-9164(95)90011-X

Watson, 1999, Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure, J Am Coll Cardiol, 33, 1549, 10.1016/S0735-1097(99)00064-9

Baggio, 1994, Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure: CoQ10 Drug Surveillance Investigators, Mol Aspects Med, s287, 10.1016/0098-2997(94)90040-X

Miller, 2004, Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches, Am Heart J, 147, 401, 10.1016/j.ahj.2003.10.021

Doval, 1994, Randomised trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA), Lancet, 344, 493, 10.1016/S0140-6736(94)91895-3

Singh, 1995, Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure, N Engl J Med, 333, 77, 10.1056/NEJM199507133330201

Torp-Pedersen, 1999, Dofetilide in patients with congestive heart failure and left ventricular dysfunction: Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group, N Engl J Med, 341, 857, 10.1056/NEJM199909163411201

Kober, 2000, Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial, Lancet, 356, 2052, 10.1016/S0140-6736(00)03402-4

Setaro, 1990, Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance, Am J Cardiol, 66, 981, 10.1016/0002-9149(90)90937-V

Packer, 1996, Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group, N Engl J Med, 335, 1107, 10.1056/NEJM199610103351504

Cohn, 1997, Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group, Circulation, 96, 856, 10.1161/01.CIR.96.3.856

Littler, 1995, Placebo controlled trial of felodipine in patients with mild to moderate heart failure: UK Study Group, Br Heart J, 73, 428, 10.1136/hrt.73.5.428

Udelson, 2000, Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction, Am Heart J, 139, 503, 10.1016/S0002-8703(00)90095-4

Thackray, 2000, Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT, Eur J Heart Fail, 2, 209, 10.1016/S1388-9842(00)00080-5

Page, 2000, Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem, Arch Intern Med, 160, 777, 10.1001/archinte.160.6.777

Feenstra, 2002, Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study, Arch Intern Med, 162, 265, 10.1001/archinte.162.3.265

Mamdani, 2004, Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study, Lancet, 363, 1751, 10.1016/S0140-6736(04)16299-5

Delea, 2003, Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study, Diabetes Care, 26, 2983, 10.2337/diacare.26.11.2983

Dargie, 2007, A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure, J Am Coll Cardiol, 49, 1696, 10.1016/j.jacc.2006.10.077

Lago, 2007, Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials, Lancet, 370, 1129, 10.1016/S0140-6736(07)61514-1

Home, 2009, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, 373, 2125, 10.1016/S0140-6736(09)60953-3

Giles, 2010, Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease, Congest Heart Fail, 16, 111, 10.1111/j.1751-7133.2010.00154.x

Komajda, 2010, Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial, Eur Heart J, 31, 824, 10.1093/eurheartj/ehp604

Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7

Edelmann, 2013, Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial, JAMA, 309, 781, 10.1001/jama.2013.905

Piller, 2011, Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Circulation, 124, 1811, 10.1161/CIRCULATIONAHA.110.012575

Abraham, 2005, In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE), J Am Coll Cardiol, 46, 57, 10.1016/j.jacc.2005.03.051

Bardy, 2005, Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure, N Engl J Med, 352, 225, 10.1056/NEJMoa043399

Abraham, 2002, Cardiac resynchronization in chronic heart failure, N Engl J Med, 346, 1845, 10.1056/NEJMoa013168

Moss, 2009, Cardiac-resynchronization therapy for the prevention of heart-failure events, N Engl J Med, 361, 1329, 10.1056/NEJMoa0906431

Tang, 2010, Cardiac-resynchronization therapy for mild-to-moderate heart failure, N Engl J Med, 363, 2385, 10.1056/NEJMoa1009540

Buxton, 1999, A randomized study of the prevention of sudden death in patients with coronary artery disease: Multicenter Unsustained Tachycardia Trial Investigators, N Engl J Med, 341, 1882, 10.1056/NEJM199912163412503

Hohnloser, 2004, Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction, N Engl J Med, 351, 2481, 10.1056/NEJMoa041489

Linde, 2008, Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms, J Am Coll Cardiol, 52, 1834, 10.1016/j.jacc.2008.08.027

Brignole, 2005, Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation, Eur Heart J, 26, 712, 10.1093/eurheartj/ehi069

Brignole, 2011, Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial, Eur Heart J, 32, 2420, 10.1093/eurheartj/ehr162

Doshi, 2005, Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study), J Cardiovasc Electrophysiol, 16, 1160, 10.1111/j.1540-8167.2005.50062.x

Gasparini, 2006, Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation, J Am Coll Cardiol, 48, 734, 10.1016/j.jacc.2006.03.056

Wilton, 2011, Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis, Heart Rhythm, 8, 1088, 10.1016/j.hrthm.2011.02.014

Upadhyay, 2008, Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies, J Am Coll Cardiol, 52, 1239, 10.1016/j.jacc.2008.06.043

Adelstein, 2011, Predicting hyperresponse among pacemaker-dependent nonischemic cardiomyopathy patients upgraded to cardiac resynchronization, J Cardiovasc Electrophysiol, 22, 905, 10.1111/j.1540-8167.2011.02018.x

Vatankulu, 2009, Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices, Am J Cardiol, 103, 1280, 10.1016/j.amjcard.2009.01.023

Setoguchi, 2009, Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure, CMAJ, 180, 611, 10.1503/cmaj.080769

Carson, 2005, Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial, J Am Coll Cardiol, 46, 2329, 10.1016/j.jacc.2005.09.016

Zareba, 2005, Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population), Am J Cardiol, 95, 1487, 10.1016/j.amjcard.2005.02.021

Mozaffarian, 2007, Prediction of mode of death in heart failure: the Seattle Heart Failure Model, Circulation, 116, 392, 10.1161/CIRCULATIONAHA.106.687103

Rickard, 2011, Predictors of response to cardiac resynchronization therapy in patients with a non-left bundle branch block morphology, Am J Cardiol, 108, 1576, 10.1016/j.amjcard.2011.07.017

Deleted in press.

Steinbeck, 2009, Defibrillator implantation early after myocardial infarction, N Engl J Med, 361, 1427, 10.1056/NEJMoa0901889

Sears, 2011, Posttraumatic stress and the implantable cardioverter-defibrillator patient: what the electrophysiologist needs to know, Circ Arrhythm Electrophysiol, 4, 242, 10.1161/CIRCEP.110.957670

Al-Khatib, 2008, Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002–2005, Circ Arrhythm Electrophysiol, 1, 240, 10.1161/CIRCEP.108.777888

Epstein, 2009, Implantable cardioverter-defibrillator prescription in the elderly, Heart Rhythm, 6, 1136, 10.1016/j.hrthm.2009.04.010

Healey, 2007, Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias, Eur Heart J, 28, 1746, 10.1093/eurheartj/ehl438

Santangeli, 2010, Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators, Ann Intern Med, 153, 592, 10.7326/0003-4819-153-9-201011020-00009

Stevenson, 2006, Selecting patients for discussion of the ICD as primary prevention for sudden death in heart failure, J Card Fail, 12, 407, 10.1016/j.cardfail.2006.06.001

Lampert, 2010, HRS expert consensus statement on the management of cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy, Heart Rhythm, 7, 1008, 10.1016/j.hrthm.2010.04.033

Young, 2003, Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial, JAMA, 289, 2685, 10.1001/jama.289.20.2685

Saxon, 2003, Resynchronization therapy for the treatment of heart failure, Circulation, 108, 1044, 10.1161/01.CIR.0000085656.57918.B1

Sipahi, 2011, Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials, Arch Intern Med, 171, 1454, 10.1001/archinternmed.2011.247

Stavrakis, 2012, The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis, J Cardiovasc Electrophysiol, 23, 163, 10.1111/j.1540-8167.2011.02144.x

Bilchick, 2010, Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients, Circulation, 122, 2022, 10.1161/CIRCULATIONAHA.110.956011

Adelstein, 2009, Usefulness of baseline electrocardiographic QRS complex pattern to predict response to cardiac resynchronization, Am J Cardiol, 103, 238, 10.1016/j.amjcard.2008.08.069

Rickard, 2010, Cardiac resynchronization therapy in non-left bundle branch block morphologies, Pacing Clin Electrophysiol, 33, 590, 10.1111/j.1540-8159.2009.02649.x

Sharma, 2012, The utility of cardiac resynchronization therapy in patients with atrial fibrillation, J Innovations Cardiac Rhythm Manage, 621

Daubert, 2009, J Am Coll Cardiol, 54, 1837, 10.1016/j.jacc.2009.08.011

Santangeli, 2011, Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis, J Interv Card Electrophysiol, 32, 125, 10.1007/s10840-011-9584-y

Barsheshet, 2011, Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy), J Am Coll Cardiol, 57, 2416, 10.1016/j.jacc.2010.12.041

Tang, 2009, Resynchronization/defibrillation for ambulatory heart failure trial: rationale and trial design, Curr Opin Cardiol, 24, 1, 10.1097/HCO.0b013e32831bc63b

Deleted in press.

2008

Ambardekar, 2009, Characteristics and in-hospital outcomes for nonadherent patients with heart failure: findings from Get With The Guidelines-Heart Failure (GWTG-HF), Am Heart J, 158, 644, 10.1016/j.ahj.2009.07.034

Kripalani, 2007, Interventions to enhance medication adherence in chronic medical conditions: a systematic review, Arch Intern Med, 167, 540, 10.1001/archinte.167.6.540

Wu, 2008, Medication adherence in patients who have heart failure: a review of the literature, Nurs Clin North Am, 43, 133, 10.1016/j.cnur.2007.10.006

Bagchi, 2007, Utilization of, and adherence to, drug therapy among Medicaid beneficiaries with congestive heart failure, Clin Ther, 29, 1771, 10.1016/j.clinthera.2007.08.015

Neily, 2002, Potential contributing factors to noncompliance with dietary sodium restriction in patients with heart failure, Am Heart J, 143, 29, 10.1067/mhj.2002.119380

van der Wal, 2010, Compliance with non-pharmacological recommendations and outcome in heart failure patients, Eur Heart J, 31, 1486, 10.1093/eurheartj/ehq091

Russell, 2008, Advanced heart failure: a call to action, Congest Heart Fail, 14, 316, 10.1111/j.1751-7133.2008.00022.x

Stevenson, 2009, INTERMACS profiles of advanced heart failure: the current picture, J Heart Lung Transplant, 28, 535, 10.1016/j.healun.2009.02.015

Travers, 2007, Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability, J Card Fail, 13, 128, 10.1016/j.cardfail.2006.10.012

Gheorghiade, 2007, Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry, Eur Heart J, 28, 980, 10.1093/eurheartj/ehl542

Klein, 2005, Circulation, 111, 2454, 10.1161/01.CIR.0000165065.82609.3D

Aranda, 2003, Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial, Am Heart J, 145, 324, 10.1067/mhj.2003.50

Brozena, 2004, A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home, J Heart Lung Transplant, 23, 1082, 10.1016/j.healun.2003.08.017

Cuffe, 2002, Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial, JAMA, 287, 1541, 10.1001/jama.287.12.1541

Elkayam, 2007, Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure, Am Heart J, 153, 98, 10.1016/j.ahj.2006.09.005

O’Connor, 1999, Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST), Am Heart J, 138, 78, 10.1016/S0002-8703(99)70250-4

Hershberger, 2003, Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure, J Card Fail, 9, 180, 10.1054/jcaf.2003.24

Gorodeski, 2009, Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure, Circ Heart Fail, 2, 320, 10.1161/CIRCHEARTFAILURE.108.839076

Cohn, 1998, A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure, N Engl J Med, 339, 1810, 10.1056/NEJM199812173392503

Hampton, 1997, Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure: Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators, Lancet, 349, 971, 10.1016/S0140-6736(96)10488-8

Lubsen, 1996, Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial, Heart, 76, 223, 10.1136/hrt.76.3.223

Packer, 1991, Effect of oral milrinone on mortality in severe chronic heart failure, N Engl J Med, 325, 1468, 10.1056/NEJM199111213252103

Metra, 2009, Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials, Eur Heart J, 30, 3015, 10.1093/eurheartj/ehp338

Oliva, 1999, Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial, Am Heart J, 138, 247, 10.1016/S0002-8703(99)70108-0

Pagani, 2009, Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device, J Am Coll Cardiol, 54, 312, 10.1016/j.jacc.2009.03.055

Alba, 2010, Impact of fixed pulmonary hypertension on post-heart transplant outcomes in bridge-to-transplant patients, J Heart Lung Transplant, 29, 1253, 10.1016/j.healun.2010.06.002

Elhenawy, 2011, Mechanical circulatory support as a bridge to transplant candidacy, J Card Surg, 26, 542, 10.1111/j.1540-8191.2011.01310.x

Nair, 2010, Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension, J Heart Lung Transplant, 29, 201, 10.1016/j.healun.2009.09.013

Miller, 2007, Use of a continuous-flow device in patients awaiting heart transplantation, N Engl J Med, 357, 885, 10.1056/NEJMoa067758

Lahpor, 2010, European results with a continuous-flow ventricular assist device for advanced heart-failure patients, Eur J Cardiothorac Surg, 37, 357

Starling, 2011, J Am Coll Cardiol, 57, 1890, 10.1016/j.jacc.2010.10.062

Grady, 2004, Longitudinal change in quality of life and impact on survival after left ventricular assist device implantation, Ann Thorac Surg, 77, 1321, 10.1016/j.athoracsur.2003.09.089

Burkhoff, 2006, A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock, Am Heart J, 152, 469.e1, 10.1016/j.ahj.2006.05.031

Greenberg, 2008, Circulation, 118, 1241, 10.1161/CIRCULATIONAHA.108.773275

Seyfarth, 2008, A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction, J Am Coll Cardiol, 52, 1584, 10.1016/j.jacc.2008.05.065

Thiele, 2005, Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock, Eur Heart J, 26, 1276, 10.1093/eurheartj/ehi161

Rose, 2001, Long-term use of a left ventricular assist device for end-stage heart failure, N Engl J Med, 345, 1435, 10.1056/NEJMoa012175

Stevenson, 2004, Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure), Circulation, 110, 975, 10.1161/01.CIR.0000139862.48167.23

Rogers, 2007, Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial, J Am Coll Cardiol, 50, 741, 10.1016/j.jacc.2007.03.063

Slaughter, 2009, Advanced heart failure treated with continuous-flow left ventricular assist device, N Engl J Med, 361, 2241, 10.1056/NEJMoa0909938

Liotta, 1962, Prolonged partial left ventricular bypass by means of an intrathoracic pump implanted in the left chest, Trans Am Soc Artif Intern Organs, 8, 90, 10.1097/00002480-196204000-00022

Holman, 2009, Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study, J Heart Lung Transplant, 28, 44, 10.1016/j.healun.2008.10.011

Hall, 2011, Clinical, molecular, and genomic changes in response to a left ventricular assist device, J Am Coll Cardiol, 57, 641, 10.1016/j.jacc.2010.11.010

Kato, 2011, Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling, Circ Heart Fail, 4, 546, 10.1161/CIRCHEARTFAILURE.111.962142

Mehra, 2006, Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006, J Heart Lung Transplant, 25, 1024, 10.1016/j.healun.2006.06.008

Stehlik, 2011, The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report–2011, J Heart Lung Transplant, 30, 1078, 10.1016/j.healun.2011.08.003

Grady, 1996, Improvement in quality of life in patients with heart failure who undergo transplantation, J Heart Lung Transplant, 15, 749

Grady, 1999, Predictors of quality of life in patients at one year after heart transplantation, J Heart Lung Transplant, 18, 202, 10.1016/S1053-2498(98)00048-5

Grady, 2007, Patterns and predictors of physical functional disability at 5 to 10 years after heart transplantation, J Heart Lung Transplant, 26, 1182, 10.1016/j.healun.2007.08.001

Habedank, 2007, Changes in exercise capacity, ventilation, and body weight following heart transplantation, Eur J Heart Fail, 9, 310, 10.1016/j.ejheart.2006.07.001

Kobashigawa, 1999, A controlled trial of exercise rehabilitation after heart transplantation, N Engl J Med, 340, 272, 10.1056/NEJM199901283400404

Salyer, 2003, Lifestyle and quality of life in long-term cardiac transplant recipients, J Heart Lung Transplant, 22, 309, 10.1016/S1053-2498(02)00552-1

Grady, 2007, Patterns and predictors of quality of life at 5 to 10 years after heart transplantation, J Heart Lung Transplant, 26, 535, 10.1016/j.healun.2007.01.042

Deng, 2000, Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity: Comparative Outcome and Clinical Profiles in Transplantation (COCPIT) Study Group, BMJ, 321, 540, 10.1136/bmj.321.7260.540

Arena, 2004, Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison, Am Heart J, 147, 354, 10.1016/j.ahj.2003.07.014

Butler, 2004, Selection of patients for heart transplantation in the current era of heart failure therapy, J Am Coll Cardiol, 43, 787, 10.1016/j.jacc.2003.08.058

Chase, 2010, Prognostic usefulness of the functional aerobic reserve in patients with heart failure, Am Heart J, 160, 922, 10.1016/j.ahj.2010.08.003

Ferreira, 2010, Ventilatory efficiency and the selection of patients for heart transplantation, Circ Heart Fail, 3, 378, 10.1161/CIRCHEARTFAILURE.108.847392

Goda, 2011, The Heart Failure Survival Score outperforms the peak oxygen consumption for heart transplantation selection in the era of device therapy, J Heart Lung Transplant, 30, 315, 10.1016/j.healun.2010.09.007

Lund, 2003, Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy, Am J Cardiol, 92, 1350, 10.1016/j.amjcard.2003.08.027

Mancini, 1991, Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure, Circulation, 83, 778, 10.1161/01.CIR.83.3.778

Klotz, 2003, Reversible pulmonary hypertension in heart transplant candidates: pretransplant evaluation and outcome after orthotopic heart transplantation, Eur J Heart Fail, 5, 645, 10.1016/S1388-9842(03)00059-X

Maron, 2010, Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy, Circ Heart Fail, 3, 574, 10.1161/CIRCHEARTFAILURE.109.922872

Rasmusson, 2007, Long-term outcomes of cardiac transplantation for peri-partum cardiomyopathy: a multiinstitutional analysis, J Heart Lung Transplant, 26, 1097, 10.1016/j.healun.2007.08.002

Zangwill, 2009, Outcomes of children with restrictive cardiomyopathy listed for heart transplant: a multi-institutional study, J Heart Lung Transplant, 28, 1335, 10.1016/j.healun.2009.06.028

Zaidi, 2007, Outcome of heart transplantation in patients with sarcoid cardiomyopathy, J Heart Lung Transplant, 26, 714, 10.1016/j.healun.2007.05.006

Wu, 2010, Clinical outcomes after cardiac transplantation in muscular dystrophy patients, J Heart Lung Transplant, 29, 432, 10.1016/j.healun.2009.08.030

Fang, 2008, Heart failure-related hospitalization in the U.S., 1979 to 2004, J Am Coll Cardiol, 52, 428, 10.1016/j.jacc.2008.03.061

Kociol, 2010, Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries, Am Heart J, 160, 885, 10.1016/j.ahj.2010.07.020

Weintraub, 2010, Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association, Circulation, 122, 1975, 10.1161/CIR.0b013e3181f9a223

Fonarow, 2007, Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE), Am Heart J, 153, 1021, 10.1016/j.ahj.2007.03.012

West, 2011, Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry, Eur J Heart Fail, 13, 945, 10.1093/eurjhf/hfr064

Baggish, 2007, Hemoglobin and N-terminal pro-brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure: results from the International Collaborative of NT-proBNP (ICON) Study, Clin Chim Acta, 381, 145, 10.1016/j.cca.2007.03.010

Gheorghiade, 2007, Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial, Arch Intern Med, 167, 1998, 10.1001/archinte.167.18.1998

Heywood, 2007, High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database, J Card Fail, 13, 422, 10.1016/j.cardfail.2007.03.011

Mohammed, 2010, Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study, Circ Heart Fail, 3, 354, 10.1161/CIRCHEARTFAILURE.109.915280

van Kimmenade, 2006, Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction?, J Am Coll Cardiol, 48, 1621, 10.1016/j.jacc.2006.06.056

van Kimmenade, 2010, Red blood cell distribution width and 1-year mortality in acute heart failure, Eur J Heart Fail, 12, 129, 10.1093/eurjhf/hfp179

Sweitzer, 2008, Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions, Am J Cardiol, 101, 1151, 10.1016/j.amjcard.2007.12.014

Yancy, 2006, Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database, J Am Coll Cardiol, 47, 76, 10.1016/j.jacc.2005.09.022

Nohria, 2002, Medical management of advanced heart failure, JAMA, 287, 628, 10.1001/jama.287.5.628

Martinez-Rumayor, 2010, Relative value of amino-terminal pro-B-type natriuretic peptide testing and radiographic standards for the diagnostic evaluation of heart failure in acutely dyspneic subjects, Biomarkers, 15, 175, 10.3109/13547500903411087

Januzzi, 2005, The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study, Am J Cardiol, 95, 948, 10.1016/j.amjcard.2004.12.032

Januzzi, 2006, NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study, Eur Heart J, 27, 330, 10.1093/eurheartj/ehi631

Green, 2008, Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea, Arch Intern Med, 168, 741, 10.1001/archinte.168.7.741

McCullough, 2002, B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study, Circulation, 106, 416, 10.1161/01.CIR.0000025242.79963.4C

Steinhart, 2009, Improving the diagnosis of acute heart failure using a validated prediction model, J Am Coll Cardiol, 54, 1515, 10.1016/j.jacc.2009.05.065

Collins, 2009, S3 detection as a diagnostic and prognostic aid in emergency department patients with acute dyspnea, Ann Emerg Med, 53, 748, 10.1016/j.annemergmed.2008.12.029

Di Somma, 2010, Use of BNP and bioimpedance to drive therapy in heart failure patients, Congest Heart Fail, 16, S56, 10.1111/j.1751-7133.2010.00162.x

Cotter, 2004, Accurate, noninvasive continuous monitoring of cardiac output by whole-body electrical bioimpedance, Chest, 125, 1431, 10.1378/chest.125.4.1431

Flaherty, 2009, Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment, J Am Coll Cardiol, 53, 254, 10.1016/j.jacc.2008.08.072

Kociol, 2010, Troponin elevation in heart failure prevalence, mechanisms, and clinical implications, J Am Coll Cardiol, 56, 1071, 10.1016/j.jacc.2010.06.016

Latini, 2007, Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure, Circulation, 116, 1242, 10.1161/CIRCULATIONAHA.106.655076

Peacock, 2008, Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis, Emerg Med J, 25, 205, 10.1136/emj.2007.050419

Fonarow, 2008, Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF, Arch Intern Med, 168, 847, 10.1001/archinte.168.8.847

Gheorghiade, 2006, Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure, JAMA, 296, 2217, 10.1001/jama.296.18.2217

Zanotti-Cavazzoni, 2009, Cardiac dysfunction in severe sepsis and septic shock, Curr Opin Crit Care, 15, 392, 10.1097/MCC.0b013e3283307a4e

Klemperer, 1996, Thyroid hormone therapy in cardiovascular disease, Prog Cardiovasc Dis, 38, 329, 10.1016/S0033-0620(96)80017-X

Granger, 2005, Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial, Lancet, 366, 2005, 10.1016/S0140-6736(05)67760-4

Metra, 2007, Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET, Eur J Heart Fail, 9, 901, 10.1016/j.ejheart.2007.05.011

Butler, 2006, Beta-blocker use and outcomes among hospitalized heart failure patients, J Am Coll Cardiol, 47, 2462, 10.1016/j.jacc.2006.03.030

Maisel, 2008, Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis, J Am Coll Cardiol, 52, 534, 10.1016/j.jacc.2008.05.010

Peacock, 2007, Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE, Cardiology, 107, 44, 10.1159/000093612

Felker, 2011, Diuretic strategies in patients with acute decompensated heart failure, N Engl J Med, 364, 797, 10.1056/NEJMoa1005419

Grosskopf, 1986, Combination of furosemide and metolazone in the treatment of severe congestive heart failure, Isr J Med Sci, 22, 787

Channer, 1994, Combination diuretic treatment in severe heart failure: a randomised controlled trial, Br Heart J, 71, 146, 10.1136/hrt.71.2.146

Sigurd, 1975, The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure: permutation trial tests in patients in long-term treatment with bumetanide, Am Heart J, 89, 163, 10.1016/0002-8703(75)90041-1

Rosenberg, 2005, Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature, Cardiovasc Drugs Ther, 19, 301, 10.1007/s10557-005-3350-2

Giamouzis, 2010, Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial, J Card Fail, 16, 922, 10.1016/j.cardfail.2010.07.246

Elkayam, 2008, Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action, Circulation, 117, 200, 10.1161/CIRCULATIONAHA.107.737106

Cleland, 2006, Practical applications of intravenous diuretic therapy in decompensated heart failure, Am J Med, 119, S26, 10.1016/j.amjmed.2006.09.014

Vasko, 1985, Furosemide absorption altered in decompensated congestive heart failure, Ann Intern Med, 102, 314, 10.7326/0003-4819-102-3-314

Wilcox, 1983, Response of the kidney to furosemide, I: effects of salt intake and renal compensation, J Lab Clin Med, 102, 450

Firth, 1988, Raised venous pressure: a direct cause of renal sodium retention in oedema?, Lancet, 1, 1033, 10.1016/S0140-6736(88)91851-X

Pivac, 1998, Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure, Int J Clin Pharmacol Res, 18, 121

Salvador, 2005, Continuous infusion versus bolus injection of loop diuretics in congestive heart failure, Cochrane Database Syst Rev, 10.1002/14651858.CD003178.pub3

Costanzo, 2007, Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure, J Am Coll Cardiol, 49, 675, 10.1016/j.jacc.2006.07.073

Bart, 2005, Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial, J Am Coll Cardiol, 46, 2043, 10.1016/j.jacc.2005.05.098

Bourge, 2005, Ultrafiltration: a new approach toward mechanical diuresis in heart failure, J Am Coll Cardiol, 46, 2052, 10.1016/j.jacc.2005.09.014

Jaski, 2003, Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients, J Card Fail, 9, 227, 10.1054/jcaf.2003.28

Costanzo, 2004, EUPHORIA trial: early ultrafiltration therapy in patients with decompensated heart failure and observed resistance to intervention with diuretic agents, J Card Fail, 10, S78, 10.1016/j.cardfail.2004.06.219

Bart, 2004, Randomized controlled trial of ultrafiltration versus usual care for hospitalized patients with heart failure: preliminary report of the Rapid Trial, J Card Fail, 10, S23, 10.1016/j.cardfail.2004.06.018

Bart, 2012, Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network, J Card Fail, 18, 176, 10.1016/j.cardfail.2011.12.009

Bart, 2012, Ultrafiltration in decompensated heart failure with cardiorenal syndrome, N Engl J Med, 367, 2296, 10.1056/NEJMoa1210357

Colucci, 2000, Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure, N Engl J Med, 343, 246, 10.1056/NEJM200007273430403

Cioffi, 2003, Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients >70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure, Am J Cardiol, 92, 1050, 10.1016/j.amjcard.2003.07.005

O’Connor, 2011, Effect of nesiritide in patients with acute decompensated heart failure, N Engl J Med, 365, 32, 10.1056/NEJMoa1100171

2002, Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial, JAMA, 287, 1531

Elkayam, 2004, Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure, Am J Cardiol, 93, 237, 10.1016/j.amjcard.2003.09.051

Cotter, 1998, Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema, Lancet, 351, 389, 10.1016/S0140-6736(97)08417-1

Elkayam, 1987, Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure, Circulation, 76, 577, 10.1161/01.CIR.76.3.577

Dupuis, 1990, Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine, J Am Coll Cardiol, 16, 923, 10.1016/S0735-1097(10)80342-0

Fung, 1994, Mechanisms of nitrate tolerance, Cardiovasc Drugs Ther, 8, 489, 10.1007/BF00877927

Mullens, 2008, Sodium nitroprusside for advanced low-output heart failure, J Am Coll Cardiol, 52, 200, 10.1016/j.jacc.2008.02.083

Alikhan, 2003, Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study, Blood Coagul Fibrinolysis, 14, 341, 10.1097/00001721-200306000-00004

Belch, 1981, Prevention of deep vein thrombosis in medical patients by low-dose heparin, Scott Med J, 26, 115, 10.1177/003693308102600205

Kleber, 2003, Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease, Am Heart J, 145, 614, 10.1067/mhj.2003.189

Samama, 1999, A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients, N Engl J Med, 341, 793, 10.1056/NEJM199909093411103

Turpie, 2000, Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial, Am J Cardiol, 86, 48M, 10.1016/S0002-9149(00)01481-8

Deleted in press.

Cohen, 2007, Thromboprophylaxis with dalteparin in medical patients: which patients benefit?, Vasc Med, 12, 123, 10.1177/1358863X07079017

Leizorovicz, 2004, Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients, Circulation, 110, 874, 10.1161/01.CIR.0000138928.83266.24

Anderson, 1950, The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure, Am Heart J, 39, 697, 10.1016/0002-8703(50)90129-3

Griffith, 1952, A study of the beneficial effects of anticoagulant therapy in congestive heart failure, Ann Intern Med, 37, 867, 10.7326/0003-4819-37-5-867

Harvey, 1950, Dicumarol prophylaxis of thromboembolic disease in congestive heart failure, N Engl J Med, 242, 208, 10.1056/NEJM195002092420603

Cohen, 2006, Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial, BMJ, 332, 325, 10.1136/bmj.38733.466748.7C

Wojnicz, 2006, Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial, Am Heart J, 152, 713.e1, 10.1016/j.ahj.2006.06.028

Tebbe, 2011, Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study, Am Heart J, 161, 322, 10.1016/j.ahj.2010.10.005

Lederle, 2011, Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline, Ann Intern Med, 155, 602, 10.7326/0003-4819-155-9-201111010-00008

Dennis, 2009, Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial, Lancet, 373, 1958, 10.1016/S0140-6736(09)60941-7

Muir, 2000, Randomized trial of graded compression stockings for prevention of deep-vein thrombosis after acute stroke, QJM, 93, 359, 10.1093/qjmed/93.6.359

Ghali, 2006, Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia, J Clin Endocrinol Metab, 91, 2145, 10.1210/jc.2005-2287

Schrier, 2006, Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia, N Engl J Med, 355, 2099, 10.1056/NEJMoa065181

Renneboog, 2006, Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits, Am J Med, 119, 71, 10.1016/j.amjmed.2005.09.026

Gheorghiade, 2007, Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials, JAMA, 297, 1332, 10.1001/jama.297.12.1332

Konstam, 2007, Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial, JAMA, 297, 1319, 10.1001/jama.297.12.1319

Naylor, 1994, Comprehensive discharge planning for the hospitalized elderly: a randomized clinical trial, Ann Intern Med, 120, 999, 10.7326/0003-4819-120-12-199406150-00005

Naylor, 2004, Transitional care of older adults hospitalized with heart failure: a randomized, controlled trial, J Am Geriatr Soc, 52, 675, 10.1111/j.1532-5415.2004.52202.x

Fonarow, 2007, Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF), Arch Intern Med, 167, 1493, 10.1001/archinte.167.14.1493

Lappe, 2004, Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program, Ann Intern Med, 141, 446, 10.7326/0003-4819-141-6-200409210-00010

Phillips, 2004, Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis, JAMA, 291, 1358, 10.1001/jama.291.11.1358

Gislason, 2007, Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes, Circulation, 116, 737, 10.1161/CIRCULATIONAHA.106.669101

Masoudi, 2004, National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction, Circulation, 110, 724, 10.1161/01.CIR.0000138934.28340.ED

Braunstein, 2003, Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure, J Am Coll Cardiol, 42, 1226, 10.1016/S0735-1097(03)00947-1

Windham, 2003, Care management interventions for older patients with congestive heart failure, Am J Manag Care, 9, 447

Fonarow, 2010, Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF), Circulation, 122, 585, 10.1161/CIRCULATIONAHA.109.934471

Fonarow, 2007, Association between performance measures and clinical outcomes for patients hospitalized with heart failure, JAMA, 297, 61, 10.1001/jama.297.1.61

Hernandez, 2010, Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure, JAMA, 303, 1716, 10.1001/jama.2010.533

2005, Agency for Healthcare Research and Quality, 30 Safe practices for better health care: fact sheet

2012, 2011 National patient safety goals

Levenson, 2000, The last six months of life for patients with congestive heart failure, J Am Geriatr Soc, 48, S101, 10.1111/j.1532-5415.2000.tb03119.x

Krumholz, 2000, Evaluating quality of care for patients with heart failure, Circulation, 101, E122, 10.1161/01.CIR.101.12.e122

Wang, 2003, Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study, Circulation, 107, 2920, 10.1161/01.CIR.0000072767.89944.6E

Maisel, 2003, Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy, Am J Cardiol, 91, 2D, 10.1016/S0002-9149(02)03373-8

Deleted in press.

Tsang, 2002, Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women, J Am Coll Cardiol, 40, 1636, 10.1016/S0735-1097(02)02373-2

Roy, 2008, Rhythm control versus rate control for atrial fibrillation and heart failure, N Engl J Med, 358, 2667, 10.1056/NEJMoa0708789

Hsu, 2004, Catheter ablation for atrial fibrillation in congestive heart failure, N Engl J Med, 351, 2373, 10.1056/NEJMoa041018

Khan, 2008, Pulmonary-vein isolation for atrial fibrillation in patients with heart failure, N Engl J Med, 359, 1778, 10.1056/NEJMoa0708234

Deleted in press.

Deleted in press.

Deleted in press.

Groenveld, 2008, Anemia and mortality in heart failure patients a systematic review and meta-analysis, J Am Coll Cardiol, 52, 818, 10.1016/j.jacc.2008.04.061

Tang, 2006, Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options, Circulation, 113, 2454, 10.1161/CIRCULATIONAHA.105.583666

Go, 2006, Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study, Circulation, 113, 2713, 10.1161/CIRCULATIONAHA.105.577577

Ezekowitz, 2003, Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure, Circulation, 107, 223, 10.1161/01.CIR.0000052622.51963.FC

Sharma, 2004, Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial, Eur Heart J, 25, 1021, 10.1016/j.ehj.2004.04.023

von Haehling, 2011, Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study, Eur J Heart Fail, 13, 656, 10.1093/eurjhf/hfr044

Kalra, 2003, Effect of anemia on exercise tolerance in chronic heart failure in men, Am J Cardiol, 91, 888, 10.1016/S0002-9149(03)00030-4

O’Meara, 2006, Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program, Circulation, 113, 986, 10.1161/CIRCULATIONAHA.105.582577

Mozaffarian, 2003, Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE), J Am Coll Cardiol, 41, 1933, 10.1016/S0735-1097(03)00425-X

Westenbrink, 2010, Bone marrow dysfunction in chronic heart failure patients, Eur J Heart Fail, 12, 676, 10.1093/eurjhf/hfq061

Silverberg, 2000, The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations, J Am Coll Cardiol, 35, 1737, 10.1016/S0735-1097(00)00613-6

Silverberg, 2001, The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study, J Am Coll Cardiol, 37, 1775, 10.1016/S0735-1097(01)01248-7

Mancini, 2003, Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure, Circulation, 107, 294, 10.1161/01.CIR.0000044914.42696.6A

Palazzuoli, 2006, Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia, Am Heart J, 152, 1096.e9, 10.1016/j.ahj.2006.08.005

Parissis, 2008, Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy, Am Heart J, 155, 751, 10.1016/j.ahj.2008.01.016

van Veldhuisen, 2007, Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia, Eur Heart J, 28, 2208, 10.1093/eurheartj/ehm328

Ghali, 2008, Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia, Circulation, 117, 526, 10.1161/CIRCULATIONAHA.107.698514

McMurray, 2009, Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial, Eur J Heart Fail, 11, 795, 10.1093/eurjhf/hfp098

Singh, 2006, Correction of anemia with epoetin alfa in chronic kidney disease, N Engl J Med, 355, 2085, 10.1056/NEJMoa065485

Drueke, 2006, Normalization of hemoglobin level in patients with chronic kidney disease and anemia, N Engl J Med, 355, 2071, 10.1056/NEJMoa062276

Swedberg, 2013, Treatment of anemia with darbepoetin alfa in systolic heart failure, N Engl J Med, 368, 1210, 10.1056/NEJMoa1214865

Deleted in press.

Anker, 2009, Ferric carboxymaltose in patients with heart failure and iron deficiency, N Engl J Med, 361, 2436, 10.1056/NEJMoa0908355

Holzapfel, 2009, Self-care and depression in patients with chronic heart failure, Heart Lung, 38, 392, 10.1016/j.hrtlng.2008.11.001

Jiang, 2011, Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study), Am J Cardiol, 107, 545, 10.1016/j.amjcard.2010.10.013

Bekelman, 2007, Symptoms, depression, and quality of life in patients with heart failure, J Card Fail, 13, 643, 10.1016/j.cardfail.2007.05.005

Freedland, 2003, Prevalence of depression in hospitalized patients with congestive heart failure, Psychosom Med, 65, 119, 10.1097/01.PSY.0000038938.67401.85

Moser, 2010, Comparison of prevalence of symptoms of depression, anxiety, and hostility in elderly patients with heart failure, myocardial infarction, and a coronary artery bypass graft, Heart Lung, 39, 378, 10.1016/j.hrtlng.2009.10.017

York, 2009, Psychobiology of depression/distress in congestive heart failure, Heart Fail Rev, 14, 35, 10.1007/s10741-008-9091-0

Unpublished data provided by the Office of Information Products and Data Analytics-CMS. CMS Administrative Claims Data, Jan 2011 - Dec 2011, from the Chronic Condition Warehouse. 2012.

Caracciolo, 1995, Comparison of surgical and medical group survival in patients with left main coronary artery disease: long-term CASS experience, Circulation, 91, 2325, 10.1161/01.CIR.91.9.2325

1992, Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina, Circulation, 86, 121, 10.1161/01.CIR.86.1.121

1984, Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina, N Engl J Med, 311, 1333, 10.1056/NEJM198411223112102

Cleland, 2011, The Heart Failure Revascularisation Trial (HEART), Eur J Heart Fail, 13, 227, 10.1093/eurjhf/hfq230

Smith, 2011, Transcatheter versus surgical aortic-valve replacement in high-risk patients, N Engl J Med, 364, 2187, 10.1056/NEJMoa1103510

Leon, 2010, Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery, N Engl J Med, 363, 1597, 10.1056/NEJMoa1008232

Feldman, 2011, Percutaneous repair or surgery for mitral regurgitation, N Engl J Med, 364, 1395, 10.1056/NEJMoa1009355

Chan, 2012, Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial, Circulation, 126, 2502, 10.1161/CIRCULATIONAHA.112.143818

Fattouch, 2009, POINT: efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: a randomized trial, J Thorac Cardiovasc Surg, 138, 278, 10.1016/j.jtcvs.2008.11.010

Franzen, 2011, MitraClip® therapy in patients with end-stage systolic heart failure, Eur J Heart Fail, 13, 569, 10.1093/eurjhf/hfr029

Jones, 2009, Coronary bypass surgery with or without surgical ventricular reconstruction, N Engl J Med, 360, 1705, 10.1056/NEJMoa0900559

Cleveland, 2011, Survival after biventricular assist device implantation: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support database, J Heart Lung Transplant, 30, 862

Klotz, 2010, Partial mechanical long-term support with the CircuLite Synergy pump as bridge-to-transplant in congestive heart failure, Thorac Cardiovasc Surg, 58, S173, 10.1055/s-0029-1240687

1983, Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery: survival data, Circulation, 68, 939, 10.1161/01.CIR.68.5.939

Takaro, 1982, Survival in subgroups of patients with left main coronary artery disease: Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive Disease, Circulation, 66, 14, 10.1161/01.CIR.66.1.14

Hu, 2011, J Am Coll Cardiol, 57, 2409, 10.1016/j.jacc.2011.01.037

Perin, 2011, A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF), Am Heart J, 161, 1078, 10.1016/j.ahj.2011.01.028

Strauer, 2010, The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study, Eur J Heart Fail, 12, 721, 10.1093/eurjhf/hfq095

Zipes, 2006, J Am Coll Cardiol, 48, e247, 10.1016/j.jacc.2006.07.010

Gelsomino, 2012, Treatment of lone atrial fibrillation: a look at the past, a view of the present and a glance at the future, Eur J Cardiothorac Surg, 41, 1284, 10.1093/ejcts/ezr222

Maybaum, 2008, Cardiac recovery during mechanical assist device support, Semin Thorac Cardiovasc Surg, 20, 234, 10.1053/j.semtcvs.2008.08.003

Burkhoff, 2006, LVAD-induced reverse remodeling: basic and clinical implications for myocardial recovery, J Card Fail, 12, 227, 10.1016/j.cardfail.2005.10.012

Coleman, 2003, Improving the quality of transitional care for persons with complex care needs, J Am Geriatr Soc, 51, 556, 10.1046/j.1532-5415.2003.51186.x

Stewart, 1998, Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care, Arch Intern Med, 158, 1067, 10.1001/archinte.158.10.1067

Stewart, 1999, Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study, Lancet, 354, 1077, 10.1016/S0140-6736(99)03428-5

Sochalski, 2009, What works in chronic care management: the case of heart failure, Health Aff (Millwood), 28, 179, 10.1377/hlthaff.28.1.179

Laramee, 2003, Case management in a heterogeneous congestive heart failure population: a randomized controlled trial, Arch Intern Med, 163, 809, 10.1001/archinte.163.7.809

Clark, 2007, Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis, BMJ, 334, 942, 10.1136/bmj.39156.536968.55

Chaudhry, 2007, Telemonitoring for patients with chronic heart failure: a systematic review, J Card Fail, 13, 56, 10.1016/j.cardfail.2006.09.001

Riegel, 2002, Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure, Arch Intern Med, 162, 705, 10.1001/archinte.162.6.705

Riegel, 2006, Randomized controlled trial of telephone case management in Hispanics of Mexican origin with heart failure, J Card Fail, 12, 211, 10.1016/j.cardfail.2006.01.005

Krumholz, 2006, A taxonomy for disease management: a scientific statement from the American Heart Association Disease Management Taxonomy Writing Group, Circulation, 114, 1432, 10.1161/CIRCULATIONAHA.106.177322

Faxon, 2004, Improving quality of care through disease management: principles and recommendations from the American Heart Association’s Expert Panel on Disease Management, Circulation, 109, 2651, 10.1161/01.CIR.0000128373.90851.7B

Rich, 1995, A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure, N Engl J Med, 333, 1190, 10.1056/NEJM199511023331806

McAlister, 2001, A systematic review of randomized trials of disease management programs in heart failure, Am J Med, 110, 378, 10.1016/S0002-9343(00)00743-9

Riegel, 2001, Heart failure disease management models, 267

Coleman, 2005, Assessing the quality of preparation for posthospital care from the patient’s perspective: the care transitions measure, Med Care, 43, 246, 10.1097/00005650-200503000-00007

Lorenz, 2008, Evidence for improving palliative care at the end of life: a systematic review, Ann Intern Med, 148, 147, 10.7326/0003-4819-148-2-200801150-00010

Hauptman, 2005, Integrating palliative care into heart failure care, Arch Intern Med, 165, 374, 10.1001/archinte.165.4.374

Adler, 2009, Palliative care in the treatment of advanced heart failure, Circulation, 120, 2597, 10.1161/CIRCULATIONAHA.109.869123

Qaseem, 2008, Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians, Ann Intern Med, 148, 141, 10.7326/0003-4819-148-2-200801150-00009

Bernheim, 2010, National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure: update on publicly reported outcomes measures based on the 2010 release, Circ Cardiovasc Qual Outcomes, 3, 459, 10.1161/CIRCOUTCOMES.110.957613

Coleman, 2003, Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs, J Am Geriatr Soc, 51, 549, 10.1046/j.1532-5415.2003.51185.x

Bernheim, 2007, Socioeconomic disparities in outcomes after acute myocardial infarction, Am Heart J, 153, 313, 10.1016/j.ahj.2006.10.037

Rahimi, 2007, Financial barriers to health care and outcomes after acute myocardial infarction, JAMA, 297, 1063, 10.1001/jama.297.10.1063

Smolderen, 2009, The association of cognitive and somatic depressive symptoms with depression recognition and outcomes after myocardial infarction, Circ Cardiovasc Qual Outcomes, 2, 328, 10.1161/CIRCOUTCOMES.109.868588

Subramanian, 2011, New predictive models of heart failure mortality using time-series measurements and ensemble models, Circ Heart Fail, 4, 456, 10.1161/CIRCHEARTFAILURE.110.958496

Foraker, 2011, Socioeconomic status, Medicaid coverage, clinical comorbidity, and rehospitalization or death after an incident heart failure hospitalization: Atherosclerosis Risk in Communities cohort (1987 to 2004), Circ Heart Fail, 4, 308, 10.1161/CIRCHEARTFAILURE.110.959031

Allen, 2011, Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure, Circ Heart Fail, 4, 293, 10.1161/CIRCHEARTFAILURE.110.959171

Dunlay, 2011, Medication adherence among community-dwelling patients with heart failure, Mayo Clin Proc, 86, 273, 10.4065/mcp.2010.0732

2010

Department of Health and Human Services; Centers for Medicare & Medicaid Services. Federal Register, Rules and Regulations. 2011. Available at: http://www.gpo.gov/fdsys/pkg/FR-2011-08-18/pdf/2011-19719.pdf Accessed July 11, 2013.

Grady, 2000, Team management of patients with heart failure: a statement for healthcare professionals from the Cardiovascular Nursing Council of the American Heart Association, Circulation, 102, 2443, 10.1161/01.CIR.102.19.2443

Desai, 2009, Statistical models and patient predictors of readmission for acute myocardial infarction: a systematic review, Circ Cardiovasc Qual Outcomes, 2, 500, 10.1161/CIRCOUTCOMES.108.832949

Verouden, 2010, Prediction of 1-year mortality with different measures of ST-segment recovery in all-comers after primary percutaneous coronary intervention for acute myocardial infarction, Circ Cardiovasc Qual Outcomes, 3, 522, 10.1161/CIRCOUTCOMES.109.923797

Allen, 2008, Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure, JAMA, 299, 2533, 10.1001/jama.299.21.2533

Goodlin, 2009, Palliative care in congestive heart failure, J Am Coll Cardiol, 54, 386, 10.1016/j.jacc.2009.02.078

Nicholas, 2011, Regional variation in the association between advance directives and end-of-life Medicare expenditures, JAMA, 306, 1447, 10.1001/jama.2011.1410

Temel, 2010, Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med, 363, 733, 10.1056/NEJMoa1000678

Swetz, 2011, Palliative medicine consultation for preparedness planning in patients receiving left ventricular assist devices as destination therapy, Mayo Clin Proc, 86, 493, 10.4065/mcp.2010.0747

Qaseem, 2011, Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society, Ann Intern Med, 155, 179, 10.7326/0003-4819-155-3-201108020-00008

Harper, 2009, Seasonal influenza in adults and children: diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America, Clin Infect Dis, 48, 1003, 10.1086/598513

Mandell, 2007, Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults, Clin Infect Dis, 44, S27, 10.1086/511159

American Heart Association. AHA Family & Friends CPR. Available at: http://www.heart.org/HEARTORG/CPRAndECC/CommunityTraining/ CommunityProducts/Family-Friendsreg-CPR_UCM_303576_Article. jsp. Accessed May 28, 2013.

Mosca, 2011, Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association, Circulation, 123, 1243, 10.1161/CIR.0b013e31820faaf8

Levine, 2012, Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association, Circulation, 125, 1058, 10.1161/CIR.0b013e3182447787

2009, Screening for depression in adults: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 151, 784, 10.7326/0003-4819-151-11-200912010-00006

2009

Jencks, 2003, Change in the quality of care delivered to Medicare beneficiaries, 1998–1999 to 2000–2001, JAMA, 289, 305, 10.1001/jama.289.3.305

US Department of Health and Human Services. Hospital Compare. http://www.medicare.gov/hospitalcompare/. Accessed July 11, 2013.

Spertus, 2005, American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care, Circulation, 111, 1703, 10.1161/01.CIR.0000157096.95223.D7

Spertus, 2010, ACCF/AHA new insights into the methodology of performance measurement: a report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures, J Am Coll Cardiol, 56, 1767, 10.1016/j.jacc.2010.09.009

Bonow, 2012, J Am Coll Cardiol, 59, 1812, 10.1016/j.jacc.2012.03.013

Bonow, 2008, ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, J Am Coll Cardiol, 52, 2113, 10.1016/j.jacc.2008.10.014

Krumholz, 2007, Measuring performance for treating heart attacks and heart failure: the case for outcomes measurement, Health Aff (Millwood), 26, 75, 10.1377/hlthaff.26.1.75

Krumholz, 2006, Circulation, 113, 456, 10.1161/CIRCULATIONAHA.105.170769